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Of the classes of receptors known, G protein-coupled receptors (GPCRs) are the largest 
group, constituting more than 800 receptors and GPCRs are the targets for more than 50% of 
available drugs (Flower, 1999). A wide range of ligands including ions, amino acids, lipid 
messengers (e.g. anandamide), purines, neuropeptides, peptide hormones, chemokines, 
glycoprotein hormones, proteases and photons signal through G protein-coupled receptors 
(Johansen, 2003). The characteristic feature of GPCRs is that they all have seven α-helical 
transmembrane domains with an extracellular N-terminus, three extracellular loops, three 
intracellular loops and an intracellular C-terminal tail (Kobilka, 2007). Additionally, they interact 
with heterotrimeric G proteins (Kobilka, 2007). While the endogenous ligands for several GPCRs 
are known, the endogenous ligands for a large fraction of the 800 family members have not been 
identified. These receptors, with no known endogenous ligands, are collectively referred to as 
orphan receptors (Chung et al., 2008).  
1.1 Classification of GPCRs 
GPCRs are assigned to one of five families based on sequence similarities within the 
seven transmembrane domains (Fredriksson, 2003). The five families in the GRAFS system of 
classification are glutamate, rhodopsin, adhesion, frizzled/taste2 and secretin. Among the five 
families, the rhodopsin family is the largest containing about 701 members, each having sequence 
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homology to rhodopsin (Kobilka, 2007). The other families of GPCRs are smaller and do not 
share sequence similarity with rhodopsin. Receptors for peptide hormones and neuropeptides 
constitute secretin family, while glutamate family of receptors include GABAB and metabotropic 
glutamate receptors (Fredriksson et al., 2003). The receptors studied in this dissertation are 
muscarinic receptors, belonging to rhodopsin family. 
1.1.1 General Characteristics of rhodopsin family members 
All receptors in rhodopsin family have characteristic fingerprint residues (Johansen, 
2003). An example of the fingerprint residues in family A receptors is the DRY sequence in the 
third transmembrane domain, which is conserved in greater than 95% of the receptors 
(Ballesteros et al., 2001). A disulfide bridge between the extracellular loops 1 and 2 is also highly 
conserved (Palczewski et al., 2000). There are also three conserved proline residues in the 
transmembrane domains V, VI and VII of rhodopsin family receptors (Johansen, 2003). 
Conserved proline residues within the alpha helical region may aid in creating different 
conformations of the receptors when it is bound by a ligand (Palczewski et al., 2000). Lastly, the 
intracellular loops 2, 3 and the cytoplasmic C tail regions are known to be involved in G protein 
coupling (Teller et al., 2001). 
1.2 Binding sites in GPCRs 
GPCRs have both orthosteric and allosteric binding sites, which are described below 
(Christopoulos and Kenakin, 2002). 
1.2.1 Orthosteric binding site 
An orthosteric site is a region where endogenous ligands including neurotransmitters, 
hormones and small molecules bind a receptor (Trumpp-Kallmeyer et al., 1992). When receptors 
are not bound by a ligand, there is a dynamic equilibrium between active and inactive 
conformations (Johansen, 2003). Receptor signaling occurs when receptors are in the active 
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conformation. Consequently, receptors may signal in the absence of a ligand (Tiberi and Caron, 
1994). This basal signaling results from a small, but measurable population of receptors that have 
attained an active state. Agonists are ligands, which bind the receptor at the orthosteric site and 
stabilize the active conformation of the receptor (Paul, 1995). Agonists have greater inclination to 
bind to the active conformation of the receptor, increasing the number of receptors in the active 
state and receptor signaling. When compared to agonists, partial agonists have a lower inclination 
for the active state of receptors (Johansen, 2003). Hence, the signaling elicited to partial agonists 
is lower than full agonists acting at the same receptor. Inverse agonists are ligands stabilizing the 
inactive conformation of the receptor by binding the orthosteric site. They shift the equilibrium 
towards the inactive state and thereby reduce the basal signaling (Johansen, 2003). Antagonists 
are ligands, which have inclination to bind the active state and inactive state of receptors equally 
(Paul, 1995). Therefore, antagonists neither increase nor decrease the signaling of a receptor. 
1.2.2 Allosteric binding site 
An allosteric site is a binding site distinct from the orthosteric site (Colquhoun, 1998). 
Allosteric agonists stabilize the active state of receptor by binding the allosteric site (Bridges and 
Lindsley, 2008). Positive allosteric modulators bind to the allosteric site and enhance the binding 
of ligands at orthosteric sites (Monod et al., 1965). Negative allosteric modulators decrease the 
affinity of the orthosteric ligands by binding to allosteric sites (Johansen, 2003). Binding of 
neutral allosteric ligands to allosteric site have no effect on the orthosteric site binding and just 
serve to antagonize the binding of other allosteric ligands (Christopoulos and Kenakin, 2002).  
In recent times, there is an effort to develop allosteric ligands as they seem promising to 
achieve selectivity and signaling not achievable with orthosteric ligands (Gregory et al., 2010). 
1.3 G protein signaling 
GPCRs signal through heterotrimeric G proteins consisting of α, β and γ subunits (Surya 
et al., 1998; Cabrera-Vera et al., 2003). While α subunits function alone, β and γ subunits 
4 
 
function as heterodimers (Hepler and Gilman, 1992). Alpha subunits have a GTP/GDP binding 
switch, which serves for activation and deactivation of G protein signaling (Weiss et al., 1988). 
Agonist binding to GPCRs results in coupling of G proteins to receptors (Ehlert, 1985). The 
complex of agonist-bound receptor coupled with G protein has a conformation, which favors the 
exchange of GDP from the Gα subunit for GTP (Christopoulos and Kenakin, 2002). The 
heterotrimer dissociates from the receptor with the translocation and signaling of Gα and Gβγ 
subunits through interaction with effector molecules (Neer, 1995). The intrinsic GTPase activity 
of Gα subunits terminates signaling by hydrolysis of GTP molecule in Gα subunit to GDP 
(Hepler and Gilman, 1992). G protein signaling is chiefly dependent on the type of Gα associated 
with Gβγ. Gα subunits are divided into four major groups based on their sequence similarity. Gαs, 
Gαq and Gα12/13 proteins activate adenylate cyclase, phospholipase C and Rho family of GTPases, 
respectively (Simon et al., 1991). Gαi proteins inhibit adenylate cyclase enzyme (Woehler and 
Ponimaskin, 2009). 
1.4 History of muscarinic receptors 
Mushrooms have been used in various cultures for religious ceremonies for many years. 
Muscarine was extracted from Amanita muscaria, a  mushroom used in several religious cultures 
(Brown, 1989). In frogs, muscarine decreased the heart rate, stopping heart beat at higher 
concentrations (Brown, 1989). Further, muscarine contracted the smooth muscle of the stomach 
and intestine and caused secretion of tears, saliva and mucus (Brown, 1989). Acetylcholine, a 
normal component of animal tissue, also had the same action as muscarine in decreasing heart 
rate and contracting smooth muscle. In 1921, Loewi performed experiments to prove that the 
substance released by the vagus nerve is acetylcholine (Brown, 1989). Two frog hearts were used 
in their study. The vagus nerve leading to one of the frog’s heart was stimulated. This slowed 
down the heart beat. The fluid surrounding the stimulated heart was collected and named as 
vagustoff. When vagustoff was introduced into the second frog heart, the heart beat stopped. 
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While physostigmine, an inhibitor of acetylcholinesterase potentiated the decrease in heart rate 
caused by vagustoff, atropine blocked the decrease in heart rate. Vagustoff was unstable in alkali 
and in serum (Brown, 1989). It was later identified that acetylcholine was the key ingredient in 
vagustoff. Acetylcholine also activates salivary, lacrimal and sweat glands to release their 
secretions (Brown, 1989). Acetylcholine is not a circulating hormone and released in the synapse, 
only in response to the activation of parasympathetic nerves. Acetylcholine mediates various 
effects such as glandular secretion, decrease in heart rate and contraction of smooth and skeletal 
muscles by acting through acetylcholine receptors.  
Acetylcholine receptors respond to the neurotransmitter acetylcholine and there are two 
different types: nicotinic and muscarinic acetylcholine receptors. Nicotinic acetylcholine 
receptors or nicotinic receptors are ligand-gated ion-channel receptors, which respond to nicotine. 
Nicotinic receptors are present in the central nervous system, peripheral nervous system and in 
skeletal muscles.  
Muscarinic acetylcholine receptors or muscarinic receptors are GPCRs and are the 
receptors studied in my dissertation. In addition to acetylcholine, muscarinic receptors respond to 
muscarine and are present both in the central nervous system as well as in the cells innervated by 
the parasympathetic nervous system. The binding, signaling and localization of muscarinic 
receptors are described below. 
1.5 Characterization of muscarinic receptor subtypes 
Muscarinic receptors were purified from porcine brain and heart using affinity 
chromatography (Haga and Haga, 1983; Peterson et al., 1984). From the purified muscarinic 
receptors, peptide sequences were obtained to serve as probes for cDNAs encoding full-length 
muscarinic receptors. Five subtypes of muscarinic receptors were cloned in many species 
including humans and rats (Kubo et al., 1986a; Kubo et al., 1986b; Bonner et al., 1987; Bonner et 
al., 1988). Based on the primary sequence of muscarinic receptors, it was predicted that they have 
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a seven transmembrane spanning domain similar to those identified in rhodopsin and the β2-
adrenergic receptor. Comparison of the sequences of the muscarinic receptor subtypes revealed a 
significant amount of sequence homology in the transmembrane regions. The greatest variability 
occurred in the amino and carboxyl termini as well as the third intracellular (i3) loop (Hulme et 
al., 1990). Five different genes code for the five subtypes of muscarinic receptor and in humans, 
these muscarinic receptor genes are mapped to chromosomes 11q12-13 (M1), 7q35-36 (M2), 1q 
43-44 (M3), 11p12-11.2 (M4) and 15q26 (M5) (Caulfield and Birdsall, 1998). Muscarinic receptor 
genes do not have introns within their coding regions (Caulfield and Birdsall, 1998). 
The binding site for acetylcholine in muscarinic receptors is predicted to be near the 
extracellular region adjoining TM3 with amino acids in TM3, TM6 and TM7 involved in ligand 
binding (Caulfield and Birdsall, 1998). A very high sequence homology between the muscarinic 
receptor subtypes around the orthosteric binding site, is the limitation for having subtype-specific 
ligands for muscarinic receptors (Curtis et al., 1989). Acetylcholine, carbachol, muscarine, 
pilocarpine, oxotremorine-M, metoclopramide, aceclidine and bethanechol are non-selective 
muscarinic agonists (Ehlert et al., 1996). McN-A-343, xanomeline and CDD-0097 are M1 
selective agonists. L-689,660 is selective for M1 and M3 receptors (Hulme et al., 1990; Caulfield 
and Birdsall, 1998). Sabcomeline, xanomeline and milameline are partial agonists at muscarinic 
receptors with no subtype-selectivity (Wood et al., 1999).   
The commonly used antagonists, scopolamine, atropine, N-methylscopalamine (NMS) 
and quinuclidinyl benzilate (QNB) do not distinguish between the different muscarinic receptor 
subtypes (Hulme et al., 1990; Bolden et al., 1992). AF-DX 116, AF-DX 384, himbacine, 
methoctramine and tripitramine are selective for M2 receptors (Eglen et al., 1999). Pirenzepine, 
telenzepine and muscarinic toxin 7 has higher affinity for M1 receptors (Eglen et al., 1999). 4-
DAMP, p-fluorohexahydro-sila-difenidol and darifenacin are selective for M3 receptors (Eglen et 
al., 1996). Tropicamide, muscarinic toxin 3, himbacine and AF-DX 384 have high affinity for M4 
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receptors (Eglen et al., 1999). There are no selective antagonists for M5 receptors (Hulme et al., 
1990; Caulfield and Birdsall, 1998). 
Because of the high sequence homology around the orthosteric binding site and 
identification of allosteric binding sites in muscarinic receptors, a number of allosteric ligands 
were developed. Gallamine was identified as a negative allosteric modulator for M2 receptors 
(Ehlert, 1988). Following gallamine, brucine and its derivatives were found to have positive and 
neutral allosteric modulation at different muscarinic receptor subtypes making them attractive 
targets for selective action at muscarinic receptor subtypes (Birdsall et al., 1997). Alcuronium and 
strychnine are positive allosteric modulators for muscarinic receptors (Jakubik et al., 1997). 
Recently, ML129 was identified as a positive allosteric modulator with selectivity to M5 receptors 
(Bridges et al., 2010). 
Due to the lack of subtype-specific ligands for different muscarinic receptors, many 
researchers developed knockout mice. Significant amount of research has been done in the past 
few decades on muscarinic receptors using radioligands and knockout mice. This led to a deeper 
understanding of the location of muscarinic receptors in the body, which is described in the 
subsequent section.  
1.6 Distribution of muscarinic receptors 
1.6.1 Nervous system 
M1 receptors are the major subtype in the cerebral cortex and hippocampus followed by 
M2 and M4 receptors (Levey, 1993). Additionally, M1 receptors are expressed in autonomic 
ganglia. M2 receptors are predominantly localized in the basal forebrain, thalamus and brainstem 
regions (Weiner and Brann, 1989; Levey et al., 1991). In the basal forebrain and thalamus, M3 
receptors are expressed to a smaller extent (Levey et al., 1994). M4 receptors are the major 
receptors in the striatum along with M1 and M2 receptors (Levey et al., 1995). M5 receptors are 
localized in the substantia nigra region (Brann et al., 1993). 
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Muscarinic receptors are localized to both dendrites and axons within neurons. For 
example, M1 receptors are localized postsynaptically in the dendrites (Ladner and Lee, 1998; 
Bartus, 2000; Porter et al., 2002). To the contrary, M2 and M4 receptors are localized in the axons 
of the presynaptic termini of cholinergic neurons, which release acetylcholine into the synapse. 
This suggests the role of M2 receptors as autoreceptors inhibiting the release of acetylcholine in 
cholinergic neurons as well as the release of other neurotransmitters in non-cholinergic neurons 
(D'Agostino et al., 1997; Iannazzo and Majewski, 2000; Zhang et al., 2002). M4 receptors are 
localized in the dendrites of the postsynaptic neurons in the striatum. M1 and M4 receptors are 
also found on the axons presynaptically in some asymmetrical excitatory synapses in the striatum 
(Hersch and Levey, 1995). 
M current is a voltage-dependent K
+ 
current in the sympathetic ganglion neurons and in 
hippocampal pyramidal neurons. Activation of muscarinic receptors by muscarinic agonists 
ablates this current and causes depolarization of plasma membrane. In M1 knockout mice, 
muscarinic receptor agonist did not mediate the ablation of M current. Further, muscarinic 
agonists induce the formation of seizures in wild-type mouse. Additionally, M1 knockout mice 
were resistant to the muscarinic agonist-induced seizures, suggesting the role of M1 receptors in 
the ablation of M current and initiation of epileptic seizures induced by muscarinic agonists 
(Hamilton et al., 1997). Activation of muscarinic receptors by muscarine is responsible for 
hippocampal γ oscillations. Hippocampal γ oscillations stimulated by muscarine were completely 
abrogated in the M1 knockout mice, whereas knockout mice of M2, M3, M4 or M5 had 
hippocampal γ oscillations comparable to wild-type (Fisahn et al., 2002). M1 and M3 receptors 
were also shown to activate mitogen activated protein kinases (MAPKs). The MAPK pathway in 
the cortex and hippocampus has been shown to be important in learning and memory, amyloid 
protein processing, and neuronal plasticity (Hamilton and Nathanson, 2001). Activation of ERK 
1/2 protein was significantly impaired in the M1 knockout mice as well as in PC12 cells treated 
with a toxin specific for M1 receptor compared to wild-type mice. This suggests that the M1 
9 
 
receptor is the key receptor involved in MAPK activation in the mouse forebrain (Berkeley and 
Levey, 2000). 
1.6.2 Eye 
Muscarinic receptors are expressed in the eye and mediate contraction of the iris 
sphincter and ciliary body. M3 receptors are the predominant subtype of receptor expressed in 
both the iris sphincter and ciliary body and are known to mediate contraction (Zhang et al., 1995). 
Contraction of the iris leads to pupillary constriction while contraction of the ciliary body leads to 
accommodation. Contraction of the ciliary muscle also opens the trabecular network in the angle 
of the eye, facilitating the draining of aqueous humor. This particular response is useful in the 
treatment of glaucoma, a disease in which there is an increase in intraocular pressure. Muscarinic 
agonists (carbachol and pilocarpine) used in the treatment of glaucoma cause an increase in the 
outflow of aqueous humor and a reduction in intraocular pressure. 
M1, M2, M4 and M5 receptors are also expressed in the eye, though to a lesser extent than 
M3. M1, M2 and M4 receptors are expressed in the iris, whereas M5 is expressed in the ciliary 
body (Gil et al., 1997). 
1.6.3 Salivary glands 
In the submaxillary gland, M3 and M1 receptors are predominately expressed along with 
fewer M2 receptors (Maeda et al., 1988; Dorje et al., 1991; Levey, 1993). Autoantibodies to M3 
muscarinic receptors were produced in patients with the rare autoimmune disease Sjogren’s 
syndrome (Waterman et al., 2000). These autoantibodies act as antagonists at M3 receptors 
expressed on salivary glands, inhibiting the secretion of saliva resulting in a condition of dry 
mouth called called xerostomia. M3 receptor agonists are used to induce salivation in patients 





Muscarinic receptors are expressed in the heart and they decrease the heart rate in 
response to parasympathetic stimulation. M2 receptors are the major subtype of muscarinic 
receptors expressed in the heart (Maeda et al., 1988; Levey, 1993). Atria contain only M2 
receptors (Dorje et al., 1991). In the ventricles apart from M2 receptors, trace amounts of M3 and 
M5 receptors are present (Krejci and Tucek, 2002; Myslivecek et al., 2008). M2 receptors couple 
with Gi proteins. In cardiac atrial myocytes, acetylcholine activation of M2 receptors causes the 
Gβγ subunit to activate inwardly rectifying K
+
 channels (Kir) (Yamada et al., 1998). This causes 
the channel to open and release K
+
 ions outside the cell and cause hyperpolarization of the cells 
(Yamada et al., 1998). Thereby, M2 receptors decreases the depolarization caused by sympathetic 
stimulation of cardiac cells. 
1.6.5 Lungs 
Muscarinic receptors are expressed in the lungs and they mediate contraction of airway 
smooth muscles and secretion of mucus. M1 and M3 receptors are expressed in the airway glands 
(White, 1995), while M2 and M3 receptor are the prominent subtypes expressed in the airway 
smooth muscle. Smooth muscle contraction in lungs are mediated by M3 receptors (Esqueda et 
al., 1996). Apart from M3 receptors, M2 receptors also mediate contraction of smooth muscles 
indirectly by opposing the relaxation produced by β2-adrenergic receptors (Proskocil and Fryer, 
2005). Airway hyperreactivity is a condition, where the neuronal/ inhibitory M2 receptors are not 
functional leading to increased acetylcholine in the synapse and hence increased smooth muscle 
contractility. In patients suffering from inflammatory conditions such as asthma, eosinophil major 
basic protein and eosinophil peroxidase are identified to act as an endogenous allosteric 
antagonist for M2 receptor mediating airway hyperreactivity (Jacoby et al., 1993). As a result of 
antagonism of M2 receptors, the inhibition of synaptic acetylcholine release by M2 autoreceptors 
is lost and increased smooth muscle contractility happens through acetylcholine acting on M3 
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receptors in the airway smooth muscles. M3 receptor selective antagonists like ipratropium or 
tiotropium are used in the treatment of chronic obstructive pulmonary disease (COPD). 
1.6.6 Stomach 
Muscarinic receptors expressed in stomach are responsible for acid secretion. In stomach, 
there are three different gastric cells - the enterochromaffin like (ECL) cells producing histamine, 
the G cells secreting gastrin and the D cells producing somatostatin, all of which control gastric 
acid secretion. Muscarinic receptors are expressed on all these cells as well as on the parietal cells 
secreting hydrochloric acid. For example, M3 receptors are present on the parietal cells along with 
some M5 receptors (Aihara et al., 2005). Further, M1 receptors are expressed in ECL cells, 
regulating histamine release. Additionally, M2 and M4 receptors are present on the D cells (Tobin 
et al., 2009) and activation of muscarinic receptors in D cells inhibit the release of somatostatin. 
Muscarinic receptor activation in the gastric cells results in secretion of gastrin. Histamine and 
gastrin facilitate acid secretion from the parietal cells. To the contrary, somatostatin inhibits acid 
secretion. 
1.6.7 Gastrointestinal tract 
In the ileum, two subtypes of muscarinic receptors are expressed and they mediate 
gastrointestinal motility through smooth muscle contraction (Eglen, 1996). M2 receptors are the 
major fraction of muscarinic receptors in the ileum while M3 receptors represent the minor 
fraction (Candell et al., 1990). M3 receptor activation contracts smooth muscles directly, through 
calcium release. On the other hand, activation of M2 receptor has an opposing effect on the 
relaxation produced by other agents that increase the cAMP levels (Ehlert et al., 1999). Since M3 
receptor’s contractile action in the smooth muscles are dominant, antagonists for M3 receptors are 




1.6.8 Urinary bladder  
M1, M2, M3 and M4 receptors are expressed in the urinary bladder (Abrams et al., 2006). 
Contraction mediated by M3 receptors present on the detrusor muscle is responsible for 
micturition (Matsui et al., 2000). M2 receptors present on the detrusor muscle indirectly mediate 
contraction by decreasing cAMP production. M3 receptor antagonists are used to treat overactive 
bladder (Abrams et al., 2006).  
1.7 Muscarinic receptor signaling 
M1, M3 and M5 receptors couple with Gq/11 proteins and activate phospholipase C 
(Hammer, 1980; Peralta et al., 1988). Activated phospholipase C catalyzes the breakdown of 
phosphoinositide 4, 5 bisphosphate (PIP2) to inositol triphosphate (IP3) and diacylglycerol. IP3 
activates IP3 receptors in the endoplasmic reticulum and releases Ca
2+
 from the endoplasmic 
reticulum. Diacylglycerol along with Ca
2+ 
activates protein kinase C, which phosphorylates the 
receptor and tertiary messenger proteins. Released Ca
2+
 also activates calcium/calmodulin 
dependent kinases including myosin light chain kinase (MLCK). In turn, MLCK phosphorylates 
myosin, which causes smooth muscles to contract. Through this mechanism, smooth muscle 
contraction in gastrointestinal tract and lungs are mediated by M3 receptors. In vascular smooth 
muscles, activated calcium/calmodulin dependent kinases activate nitric oxide synthase (NOS) 
(Furchgott, 1999). NOS converts L-arginine to nitric oxide (NO). NO diffuses across the vascular 
smooth muscle and activates guanylyl cyclase resulting in the production of cGMP, which 
mediates vasodilation in the arteries (Furchgott, 1999). Apart from Gq mediated signaling, M3 
receptors are also shown to remodel the actin cytoskeleton by signaling through the small G 
proteins Rho and cdc42 in SH-SY5Y cells (Linseman et al., 2000). 
M2 and M4 receptors couple with Gi/o proteins and inhibit adenylate cyclase (Parker et al., 
1991; Migeon et al., 1995). Thereby M2 and M4 receptors decrease cAMP production (Kashihara 
et al., 1992).  
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1.8 Regulation of GPCR signaling 
The extent and duration of agonist-dependent GPCR signaling is highly regulated. This 
regulation occurs in four steps: desensitization, internalization and recycling or downregulation 
which is described below (Ferguson, 2001). 
1.8.1 Desensitization 
Prolonged exposure to agonists desensitizes receptors. Desensitization is defined as loss 
of response (receptor signaling) in the continued presence of agonist (Ferguson et al., 1998). The 
entire process of GPCR desensitization happens in seconds to minutes (Waugh et al., 1999). 
Desensitization involves phosphorylation of specific serine and threonine residues in the 
cytoplasmic regions (third intracellular loop and/or C-terminus) of the receptor and uncoupling of 
the receptors from G proteins (Lefkowitz, 1998). Phosphorylation of agonist-activated GPCRs 
can be mediated by G protein-coupled receptor kinases (GRKs), second messenger-dependent 
protein kinases (protein kinases A and C) or casein kinases (Ferguson, 2001). GRKs are specific 
and target only activated GPCRs when compared to other kinases, which phosphorylate GPCRs 
in a heterologous manner (Benovic et al., 1986; Lee and Fraser, 1993). Seven different GRKs are 
expressed in mammals (Premont and Gainetdinov, 2007). GRKs 1 and 7 are visual GRKs and are 
expressed in the eyes. GRK 4 is also expressed tissue specifically in testis. To the contrary, GRKs 
2, 3, 5 and 6 are widely distributed and expressed in all tissues. While GRKs 4, 5 and 6 are 
localized to the plasma membrane, GRKs 2 and 3 are cytosolic and associate with Gβγ subunits 
to phosphorylate activated receptors (Pitcher et al., 1992).  
Once phosphorylated, regions in GPCRs are bound by arrestin molecules, and arrestins 
prevent the receptors to couple from G proteins (Luttrell and Lefkowitz, 2002). In mammalian 
cells, there are four arrestins numbered from 1-4 (Premont and Gainetdinov, 2007). Arrestins 1 
and 4 are visual arrestins and have a limited distribution in the eyes. However, arrestins 2 and 3 
also represented as β-arrestins 1 and 2 are widely expressed in all tissues and are responsible for 
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regulation of non-visual GPCR signaling (Attramadal et al., 1992). Following desensitization, 
agonist-activated GPCRs undergo internalization. 
1.8.2 Internalization 
Internalization causes GPCRs to be removed from the plasma membrane in vesicles and 
transported to endosomes. Agonist-activated GPCR internalization can be characterized using 
membrane permeable and membrane impermeable radioligands. Alternatively, using density-
gradient centrifugation, receptors in the heavy fraction (plasma membrane) and light fraction 
(endosomes) can be quantified. Internalization of GPCRs occurs within minutes to hours of 
exposure to agonist.  
Agonist-bound receptors internalize using different mechanisms, and each mechanism 
relies on a specific interaction between a receptor domain and endocytic partners. Several motifs 
present in the cytoplasmic regions are implicated in internalization of GPCRs. These include 
tyrosine and dileucine based motifs (Gabilondo et al., 1997). Further, phosphorylation of key 
serine and threonine residues in the cytoplasmic domain serves as internalization determinants for 
several GPCRs (Moro et al., 1993; Tsuga et al., 1994). Additionally, ubiquitination of lysine 
residues also serve as an internalization signal for several GPCRs (Wolfe et al., 2007).  
A majority of GPCRs undergo internalization by clathrin-mediated endocytosis. In this 
mechanism, agonist-activated GPCRs are phosphorylated by GRKs and the phosphorylation sites 
act as binding sites for β-arrestins. Clathrin molecules are recruited by β-arrestin molecules to 
form a clathrin coated pit, trapping the receptor (Lefkowitz, 1998; Claing et al., 2002). This pit 
invaginates forming a vesicle and then pinched off by recruitment of dynamin GTPase molecules. 
Alternatively, some GPCRs can internalize in a β-arrestin-independent manner. AP-2 adaptor 
proteins can bind directly to both clathrin and a tyrosine based motif in GPCR, resulting in 
clathrin-mediated internalization. Apart from clathrin-mediated internalization, caveolins can 
mediate internalization of some GPCRs (Shmuel et al., 2007). Regardless of the internalization 
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mechanisms (clathrin or caveolin), dynamin GTPases are important for the scission of the 
vesicles derived from clathrin and caveolin-dependent internalizations (Dessy et al., 2000; 
Gaborik et al., 2001). Following internalization, the internalized receptors can either recycle back 
to the plasma membrane in a resensitized state or be transported to the lysosomes and degraded. 
Whether a receptor recycles or degrades is determined by the sequences present in the receptor. 
1.8.3 Recycling 
Recycling refers to the trafficking of internalized receptors from endosomes back to the 
plasma membrane in a resensitized state. There are two major pathways of receptor recycling 
from endosomes: default recycling (Mayor et al., 1993; Maxfield and McGraw, 2004) or the 
targeted recycling pathway (Gage et al., 2001; Gage et al., 2005; Paasche et al., 2005). Default 
recycling occurs through the fusion of endosomes with the plasma membrane by bulk membrane 
flow and occurs most of the time when the targeted delivery to particular compartments is 
impaired (Hanyaloglu and Zastrow, 2008). Targeted recycling occurs through specific recycling 
sequences or motifs, which interact with motor and effector proteins and traffic the receptor 
containing endosomes back to the plasma membrane (Onoprishvili et al., 2003; Seck et al., 2003; 
Gardner et al., 2007). For example, the rapid recycling of β2-adrenergic receptors is dependent on 
the interaction of sequences in the C-terminus with proteins NHERF-1, NHERF-2, PDZK1 and 
NSF (Fan et al., 2001). When this sequence was mutated, recycling was aborted and the receptor 
was directed to lysosomes. Delta opioid receptors typically undergo degradation after agonist-
dependent internalization (Gage et al., 2001). When the recycling sequence of the β2 adrenergic 
receptor was conjugated to the C-termini of δ-opioid receptors, they recycled to the plasma 
membrane (Gage et al., 2001). This suggests the importance of the recycling sequence in 





Downregulation of GPCRs occurs following prolonged stimulation with agonists. While 
downregulation can mean reduction in transcription of GPCRs, we are interested in the 
downregulation at the protein level, which can be defined using membrane-permeate 
radioligands. A highly permeant radioligand for a GPCR will be a valuable tool in quantitating 
the total number of receptors expressed in a cell (intracellular and cell surface receptors). Intact, 
whole cell radioligand binding assay with a highly permeant radioligand allow one to characterize 
the reduction in receptor number, resulting from incubation of agonist over time. Majority of 
GPCRs are downregulated in lysosomes (Tsao and von Zastrow, 2000).  
1.8.4.1 Lysosomal downregulation 
Lysosomes are the primary degradative organelles of the cell. Proteins for degradation in 
lysosomes are received through endocytosis, phagocytosis and autophagy. Lysosomal hydrolases 
are enzymes, which target substrates for lysosomal degradation and require acidic pH for their 
enzymatic activity (Saftig and Klumperman, 2009). For GPCRs downregulated in lysosomes, 
ubiquitination has been a pre-determinant (Marchese et al., 2008). The predominant mechanism 
for targeting GPCRs to lysosomes involves trafficking of ubiquitinated receptors to intralumenal 
vesicles called multivesicular bodies (MVB), which fuse with lysosomes. The sequestration of 
ubiquitinated GPCRs in MVB relies on an endosomal-sorting complex required for transport 
(ESCRT) machinery (Wollert et al., 2009). Hepatocyte growth factor-regulated tyrosine kinase 
substrate (HRS) recognizes monoubiquitinated or lysine 63 polyubiquitinated GPCRs in the 
endosomes (Haglund and Dikic, 2005). Clathrin lattices are formed in the regions of endosomes 
concentrated with ubiquitinated receptors. ESCRT1, ESCRT 2 and ESCRT 3 proteins are 
sequentially recruited by HRS and the ubiquitinated receptors are transported to multivesicular 
bodies, which fuse with lysosomes (Marchese et al., 2008).  
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Apart from the ubiquitin and ESCRT-dependent pathways of degradation, an ubiquitin-
independent pathway also exists (Tanowitz and Von Zastrow, 2002). For example, δ-opioid 
receptors normally undergo ubiquitin and ESCRT-dependent lysosomal targeting. When all the 
cytoplasmic lysine residues of δ-opioid receptors are mutated to arginine, they still underwent 
agonist-promoted downregulation similar to the wild-type receptor indicating the presence of 
ubiquitin-independent downregulation in mutant δ-opioid receptors (Tanowitz and Von Zastrow, 
2002). The mutant receptor was shown to be bound by HRS and GPCR associated sorting protein 
(GASP) for its delivery to lysosomes independent of ESCRT machinery and ubiquitin (Whistler 
et al., 2002). Protease-activated receptor 1 (PAR1) also undergoes lysosomal degradation 
independent of ubiquitin and ESCRT machinery (Gullapalli et al., 2006). Sorting nexin 1, a 
protein, which localizes to early endosomes, was shown to be involved in the delivery of PAR1 
receptors to the lysosomes (Worby and Dixon, 2002).  
Upon prolonged agonist-exposure, most GPCRs are targeted to the lysosomes for 
proteolytic degradation (Shenoy, 2007; Marchese et al., 2008). For example, GFP tagged CXCR4 
receptors colocalize with the lysosomal marker LAMP1 after agonist stimulation in HEK 293 
cells (Marchese and Benovic, 2001). Similarly, agonist-stimulated β2-adrenergic receptor was 
ubiquitinated by the E3 ligase Nedd4, which targets it to the lysosomes for degradation (Shenoy 
et al., 2008). While the vast majority of GPCRs are targeted to lysosomes for degradation after 
agonist-stimulation, a small fraction of GPCRs are not degraded in the lysosomes. This is 
highlighted by the fact that lysosomal inhibitors had little or no effect on the agonist-induced 
downregulation of μ opioid receptors and histamine H1 receptors (Chaturvedi et al., 2001; 
Hishinuma et al., 2010). To the contrary, the downregulation of platelet activating factor receptor 
(PAFR) is different and takes place both in the proteasomes and lysosomes as specific lysosomal 
protease and proteasomal inhibitors decreased the agonist-induced downregulation of PAFR 
(Dupre et al., 2003). Overexpression of dominant negative Rab7, a protein involved in the 
trafficking of cargo from early endosomes to late endosomes, inhibited the downregulation of 
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PAFR confirming  the trafficking of PAFR to lysosomes (Dupre et al., 2003). These findings 
suggest that degradation of some GPCRs may take place in proteasomes. 
1.8.4.2 Proteasomal downregulation 
Proteasomes are protein complexes composed of two subunits: a 19S regulatory subunit 
and a 20S catalytic subunit together forming a 26S complex (Murata et al., 2009). The 20S 
proteasome is a cylindrical unit composed of four heptameric rings: two outer alpha rings and two 
inner beta rings. The alpha rings serve to regulate the entry of proteins into the beta rings and the 
beta rings have the catalytic activity. The major classes of enzymes present in the beta rings are 
caspase-like, trypsin-like and chymotrypsin-like (Myung et al., 2001). The 19S regulatory subunit 
consists of a lid and a base attached to the 20S catalytic subunit. The base contains six ATPases 
and three non-ATPases proteins, while the lid contains nine non-ATPase proteins. The lid is 
responsible for identification of polyubiquitinated proteins and deubiquitination (Murata et al., 
2009). The deubiquitnated proteins are unfolded and then threaded into the 20S alpha rings by the 
ATPase proteins in the 19S base (Glickman and Ciechanover, 2002). 
1.8.5 Role of Rab proteins in trafficking of GPCRs 
Trafficking of proteins between intracellular organelles is regulated by small GTP 
proteins called Rabs  (Jordens et al., 2005). Rab proteins belong to the Ras GTPase superfamily 
(Martinez and Goud, 1998). More than 60 Rab proteins have been identified in mammalian cells 
and they are involved in the transport of proteins from one intracellular compartment to another. 
The various steps involved in Rab-mediated transport of proteins involve selection of cargo, 
transport of cargo in vesicles, delivery of vesicles to target compartment via molecular motors 
along the microtubule or actin filament systems, and fusion of the vesicle with the target 
membrane (Hammer and Wu, 2002; Grosshans et al., 2006). 
 Lipid modification of cysteine residues of Rabs anchors them to membranes. The lipid 
anchor is concealed by a GDP displacement inhibitor protein (GDI). A GDI displacement factor 
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protein (GDF) displaces the GDI and facilitates the membrane insertion of Rab proteins. Rabs are 
activated by guanine nucleotide exchange factors (GEF), which catalyzes the exchange of GDP to 
GTP. Rabs cycle between GTP-bound and GDP-bound states. Following activation of Rabs, 
effector proteins bind and the vesicles are transported. Once the vesicle fuses with membrane of 
the target organelle, GTP in active Rabs are hydrolyzed by specific GTPase activator proteins 
(GAP) (Grosshans et al., 2006). The most commonly studied Rabs in trafficking of GPCRs are 
Rab1, Rab2, Rab3, Rab4, Rab5, Rab7 and Rab11. Rab1 is involved in the transport of vesicles 
from endoplasmic reticulum to the golgi, while Rab2 is implicated in the retrograde transport of 
vesicles from the golgi to the endoplasmic reticulum (Zerial and McBride, 2001). Rab3 proteins 
are engaged in the secretion of proteins or exocytosis (Stenmark, 2009). Rab4 proteins are 
involved in the transport of vesicles from sorting endosomes to the plasma membrane in the fast 
recycling pathway, while Rab11 proteins mediate the slow recycling of proteins from the sorting 
endosomes to the plasma membrane via the perinuclear recycling compartment (Ullrich et al., 
1996; Innamorati et al., 2001). Rab5 is involved in both endocytosis of receptors from the plasma 
membrane to early endosomes and for endosome-endosome fusion (Seachrist et al., 2002). Rab7 
proteins are involved in the transport of proteins from sorting endosomes to late endosomes, 
which then mature into lysosomes (Zerial and McBride, 2001).  
1.8.6 Muscarinic receptor trafficking 
Regulation of muscarinic receptor signaling follows the same steps of regulation of 
GPCR signaling as described above.  
Desensitization of muscarinic receptors includes phosphorylation of the receptors by 
kinases and binding of β-arrestin. The desensitization of muscarinic receptors takes place within 
minutes of exposure to agonists (Tobin et al., 1992; Waugh et al., 1999). Agonist-stimulated 
desensitization of muscarinic receptors is initiated by the activity of a GRK, which 
phosphorylates the receptor (van Koppen and Kaiser, 2003). The phosphorylated receptor is then 
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bound by β-arrestin molecules (Vogler et al., 1999). Bound β-arrestin sequesters the receptor 
from coupling with G proteins and thus ceases receptor signaling. Beta-arrestin recruits AP2 and 
clathrin to remove the receptor from the plasma membrane via clathrin-mediated endocytosis 
(Claing et al., 2002). The clathrin coated pit matures to form a vesicle, which is excised from the 
plasma membrane by dynamin GTPase (van Koppen, 2001).  
M1, M3, M4 and M5 receptors are known to follow the above mentioned pathway (Tolbert 
and Lameh, 1996; Tsuga et al., 1998b; Vogler et al., 1999). Expression of a dominant negative β-
arrestin mutant in HEK293 cells decreased the internalization of M1, M3 and M4 receptors with no 
significant effect on the internalization of M2 receptors. Similarly, expression of dominant 
negative clathrin hub mutant inhibited the internalization of M1, M3 and M4 receptors with no 
change in the internalization of M2 receptors in HEK293 cells (Vogler et al., 1999). In mouse 
embryonic fibroblasts (MEF), M2 receptors have been shown to internalize in a β-arrestin and 
clathrin-dependent fashion (Jones et al., 2006). This suggests that M2 receptors internalize in a β-
arrestin, clathrin-independent and clathrin-dependent fashion in HEK293 cells and MEF cells 
respectively. Additionally, Rab5 proteins have been implicated in the internalization of 
muscarinic receptors. For example, internalization of M4 receptors is regulated by Rab5 
(Volpicelli et al., 2001).  
Following agonist-induced internalization, recycling of muscarinic receptors takes place. 
For example, after internalization, M4 receptors are localized in perinuclear endosomes along 
with Rab11 from where they slowly recycle to the plasma membrane (Volpicelli et al., 2002). In 
addition, elongation factor 1A was shown to enhance recycling of M4 receptors following 
agonist-induced internalization (McClatchy et al., 2006). M1, M2 and M3 receptors recycle 
following agonist-induced internalization (Koenig and Edwardson, 1996; Roseberry and Hosey, 
1999; Shmuel et al., 2007). Previously, the recycling of M5 receptors was not characterized. 
Agonist-induced downregulation of muscarinic receptors takes place after prolonged 
incubation with muscarinic receptor agonists. The downregulation of M1, M2, M3 and M4 
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receptors have been characterized in different cell types including U293, CHO, HEK293 and At-
T20 cells (Lameh et al., 1992; Lenz et al., 1994; Roseberry and Hosey, 1999; Shockley et al., 
1999). Previously, the agonist-induced downregulation of M5 receptors have not been studied. 
Although, there is a lot known about the signaling and trafficking of muscarinic 
receptors, there are still certain unanswered questions. In the studies presented here, a comparison 
of the trafficking of the muscarinic receptors is explored. Further, the mechanism of agonist-
induced downregulation of muscarinic receptors is studied. Moreover, we evaluated the roles of 
the i3 loop and C-terminal tail in the trafficking of M1 muscarinic receptors. 
1.9 Aims  
The primary goal of our research was to understand the trafficking of muscarinic 
acetylcholine receptors. To accomplish this goal, the following specific aims were pursued. 
1.9.1 Characterization of internalization, recycling and downregulation of muscarinic receptors 
Subtype- and cell-specific differences have been observed in agonist-dependent processes 
(desensitization, internalization, recycling and downregulation) of muscarinic receptors expressed 
in endogenous and heterologous cell lines. For example, M1 and M3 receptors internalized to a 
lesser extent than M2 and M4 receptors in CHO and COS7 cells in response to carbachol-
treatment (Koenig and Edwardson, 1996; Tsuga et al., 1998b). The rates of carbachol-induced 
internalization were significantly higher in SH-SY5Y neuroblastoma cells endogenously 
expressing M3 receptors when compared to CHO cells stably transfected with M3 receptors 
(Koenig and Edwardson, 1996). These are a few of many examples of subtype- and cell-specific 
differences in the agonist-dependent regulation of muscarinic receptors. While sequence 
differences among subtypes could account for subtype-specific differences, cell-specific 
differences are attributed to differences in the expression of proteins involved in trafficking 
between endogenous and heterologous cell lines. For example, β-arrestin 2, a protein involved in 
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agonist-induced internalization was shown to have different levels of expression in CHO, 
HEK293 and SH-SY cells (Santini et al., 2000). 
Koenig and Edwardson (1994b) have studied the delivery of M4 receptors in NG108 -15 
cells, which express them. In their study, they used propyl benzilylcholine mustard to label the 
receptors remaining on the membrane after internalization caused by carbachol treatment (Koenig 
and Edwardson, 1994b). They devised a method for calculating receptor recycling by subtracting 
the plasma membrane delivery of M4 receptors in unstimulated cells from the plasma membrane 
delivery of M4 receptors in the cells stimulated with carbachol. Based on their data, they 
developed a mathematical model for the delivery of the receptors to the membrane incorporating 
the biosynthetic, endocytic, recycling and degradation compartments (Koenig and Edwardson, 
1994a). They also found that the rate and extent of agonist-dependent internalization depends 
upon the muscarinic receptor subtype expressed in a cell line (Koenig and Edwardson, 1996). 
These observations provide further impetus to investigate the kinetics of M1-M5 receptor 
recycling and downregulation in the same cell line. Gill and Rang (1966) showed an aziridium 
ion derivative of benzilylcholine mustard (BCM) has a permanent antagonist activity with the 
muscarinic receptors. We used this derivative to alkylate receptors remaining on the plasma 
membrane, after internalization was initiated by carbachol in our recycling assays. BCM alkylates 
the muscarinic receptors at a greater rate than propyl benzilylcholine mustard allowing us to 
reduce the influence of alkylation on the rate of receptor recycling. 
To date, the agonist-dependent internalization, recycling and downregulation of all five 
subtypes of muscarinic receptor have not been characterized in one cell type. This comparison is 
important because differences in the kinetics or extent of internalization, recycling or 
downregulation would be an indication that distinct mechanisms regulate the activity of 
muscarinic receptors in a subtype-specific manner. In this aim, the carbachol-dependent 
internalization and downregulation of M1-M5 receptors in CHO cells were compared.  The 
recycling of M1-M5 receptors after a brief treatment with carbachol was also compared. Prior to 
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our study, the downregulation of M4 receptors was not studied in CHO cells. The internalization 
of M5 receptors was not studied in CHO cells and the agonist-induced downregulation and 
recycling of M5 receptors was not characterized previously. 
1.9.2 Characterization of the effect of proteasomal and lysosomal inhibitors on the 
downregulation of muscarinic receptors   
To some extent, the mechanisms of agonist-induced internalization and desensitization of 
muscarinic receptors have been worked out. The mechanisms of agonist-induced downregulation 
of muscarinic receptors are unclear. Lysosomal inhibitors (e.g., NH4Cl) have been previously 
shown to inhibit the agonist-induced downregulation of muscarinic receptors in NG-108 cells and 
pancreatic acini cells (Ray and Berman, 1989; Hootman et al., 1991) but they had no effect on the 
downregulation of muscarinic receptors in the vas deferens (Hiroshi et al., 1982). Lactacystin, a 
proteasomal inhibitor, inhibited the agonist-induced downregulation of M2 receptors in MEF cells 
(Mosser et al., 2008). In MDCK cells, only a small fraction of M1 receptors colocalize with the 
lysosomal marker Rab7 after agonist-stimulation, suggesting that there could be pathways 
alternate to the lysosomal pathway for the degradation of M1 receptors (Shmuel et al., 2007). All 
these reports prompted us to think that there could be more than just the lysosomal pathway for 
agonist-stimulated degradation of muscarinic receptors. The mechanism of downregulation of 
muscarinic receptors has not been studied previously. Hence, this aim addresses whether the 
mechanism is lysosomal or proteasomal. In particular, the effect of proteasomal inhibitors and 
lysosomal inhibitors on the carbachol-induced downregulation of muscarinic receptor subtypes 
M1-M5 is characterized. 
1.9.3 Characterization of domains in the third intracellular loop and C terminal tail of M1 
muscarinic receptors 
The domains in the third intracellular loop and C terminal tail of GPCRs are involved in various 
agonist-dependent processes (internalization, recycling and downregulation). For example, 
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Hashimoto and Morisawa (2008) identified a sequence essential for internalization and recycling 
in the third intracellular loop of M4 receptors. The recycling motif identified had no similarity 
with currently known recycling motifs for various GPCRs (Hashimoto et al., 2008). Further, the 
recycling sequence identified for M4 receptors is present in the i3 loop while the recycling signals 
of other GPCRs are in the C-tail domain (Hanyaloglu and Zastrow, 2008; Hashimoto et al., 
2008). Previously, our laboratory identified a di-cysteine motif in the i3 loop of M1 receptors that 
is involved in agonist-induced internalization (Sawyer et al., 2008). Hence, we propose to 
characterize domains in the i3 loop and C-terminal tail of M1 receptors to identify domains 
involved in agonist-dependent recycling and downregulation. To pursue this aim, two deletion 
mutants: i3 loop deletion mutant (M1 del 276-282) and C-terminal tail deletion mutant (M1 del 
447-459) were made in M1 receptors and the mutant receptors were stably expressed in CHO 
cells. Shown below is a snapshot of multiple sequence alignment of M1-M5 receptors in the 
proposed M1 deletion regions. 
M1             235 ----GGSSSS------SERSQPGAEGSPETPPGRCCRCCRAPRLLQAYSWKEEEEED--- 281 
M5             263 QRERNQASWS------SSRRSTSTTGKPSQATGPSANWAKAEQLTTCSSYPSSEDEDKPA 316 
M3             300 MKRSNRRKYGRCHFWFTTKSWKPSSEQMDQDHSSSDSWNNNDAAASLENSASSDEEDIGS 359 
M2             238 ----GRIVKP------NNNNMP---SSDDGLEHNKIQNGKAPRDPVTENCVQGEEKESSN 284 
M4             246 ----SPLMKQ------SVKKPPPGEAAREELRNGKLEEAPPPALPPPPRPVA--DKDTSN 294 
 
M1             282 -EGSMESLTS---------SEGEE-PG---SEVVIKMPMVDPEAQAPTKQPP--RSSPNT 325 
M5             317 TDPVLQVVYK---------SQGKESPGEEFSAEETEETFVKAETEKSDYDTPNYLLSPAA 367 
M3             360 ETRAIYSIVLKLPGHSTILNSTKLPSSDNLQVPEEELGMVDLERKADKLQAQKSVDDGGS 419 
M2             285 DSTSVSAVAS----------NMR--DDEITQDENTVSTSLG-----HSKDENSKQTCIRI 327 
M4             295 ESSSGSATQN----------TKERPATELSTTEATTPAMPAPPLQPRALNPASRWSKIQI 344 
 
M1             411 STINPMCYALCNKAFRDTFRLLLLCRWDKRRWRKIPKRPGS----VHRTPSRQC 460 
M5             488 STVNPICYALCNRTFRKTFKMLLLCRWKKKKVEEKLYWQGN----SKLP----- 532 
M3             537 STVNPVCYALCNKTFRTTFKMLLLCQCDKKKRRKQQYQQRQSVIFHKRAPEQAL 590 
M2             433 STINPACYALCNATFKKTFKHLLMCHYKNIGATR-------------------- 466 
M4             446 STINPACYALCNATFKKTFRHLLLCQYRNIGTAR-------------------- 479 
 
The binding and signaling parameters of the mutant receptors stably expressed in CHO 
cells were characterized. Additionally, the kinetics and extent of carbachol-induced 
internalization, recycling and downregulation of the mutant receptors were also compared with 







MATERIALS AND METHODS 
 
2.1 Materials 
Proteasome inhibitor I (PSI), E-64-d, Lactacystin and MG-132 were purchased from 
Enzo lifesciences (Farmingdale, NY). Ammonium chloride and atropine was purchased from 









H]quinuclidinyl benzylate, specific activity 50.5 Ci/mmol) were 
purchased from Perkin Elmer lifesciences (Boston, MA). Scintiverse BD cocktail was purchased 
from Fisher Scientific (Fairlawn, NJ). BCA protein assay kit was purchased from Pierce 
(Rockford, IL). Lipofectamine 2000 and geneticin were purchased from Invitrogen (Carlsbad, 
CA). Quikchange II site directed mutagenesis kit was purchased from Stratagene (La Jolla, CA). 
M1 receptor cDNA in a modified Okayama-Berg expression vector (pCD) and CHO cells stably 
expressing muscarinic receptors (M1-M5) individually were generous gifts from Dr. Tom I. 
Bonner at the National Institute of Mental Health, Bethesda, MD. Benzilylcholine mustard 
(BCM) was a kind gift of Dr. Fred Ehlert at University of California, Irvine, CA. Complete Mini 
EDTA-free protease inhibitor cocktail tablet was purchased from Roche diagnostics 
(Indianapolis, IN). GF/B-fired glass-fiber filters were purchased from Whatman (Clifton, NJ). 
2.2 Cloning and site-directed mutagenesis 
 Deletion mutations were created using carefully designed mutagenesis primers following 
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Quikchange II site directed mutagenesis protocol. M1 del 276-282 DNA in pCD vector was 
created by amplifying M1 wild-type DNA in pCD vector using Quikchange II XL site directed 
mutagenesis kit with mutagenesis primers 5’ CCTACAGCTGGAAGGGCTCCATGGAGTCC 3’ 
and 5’GGACTCCATGGAGCCCTTCCAGCTGTAGG 3’. After mutagenesis, M1 del 276-282 
DNA was amplified using primers 5’ GCAGAGGAATTCGTCATGAACACTTCAGCCCCAC 
3’ and 5’ GCAGAGGCGGCCGCTCAGCATTGGCGGGAG 3’ to generate M1 del 276-282 
DNA with Eco RI and Not I restriction sequences at the ends. For subcloning into pIRES neo 
vector containing mammalian selection marker aminoglycoside 3’-phosphotransferase in 
preparation for creation of stable cells, both pIRES neo vector and the PCR product was digested 
with Eco RI and Not I enzymes and ligated using T4 DNA ligase.  
Similarly, M1 del 447-459 DNA in pCD vector was created by amplifying M1 wild-type 
DNA in pCD vector using mutagenesis primers 5’ 
GCTGGCGCAAGATCCCCTGCTGATAGTCC 3’ and 5’ 
GGACTATCAGCAGGGGATCTTGCGCCAGC 3’. Following mutagenesis, M1 del 447-459 
DNA was selectively amplified using primers 5’ 
GCAGAGGAATTCGTCATGAACACTTCAGCCCCAC 3’ and 5’ 
GCAGAGGCGGCCGCTCAGCATTGGCGGGAG 3’so that the resultant PCR product has Eco 
RI and Not I restriction enzyme sequences at its ends. For subcloning into pIRES neo vector, both 
pIRES neo vector and the PCR product was digested with Eco RI and Not I enzymes and ligated 
using T4 DNA ligase enzyme. All the plasmids generated using mutagenesis or subcloning were 
sequenced at OSU Stillwater core DNA sequencing facility and verified.   
2.3 Cell culture    
 CHO cells with a low passage number were plated in a 35 mm cell culture dish at a cell 
density of 3.3 x 10
5
 cells per ml of F-12K media supplemented with 10% FBS. The following day 
M1 del 276-282 or M1 del 447-459 DNA in pIRESneo vector was transfected using Lipofectamine 
2000 following the manufacturer’s protocol. The transfected cells were trypsinized and passed 
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into 10 cm cell culture dishes at a ratio of 1 in 1000 or less on the third day. A concentration of 
500 µg of geneticin (Invitrogen, CA) per ml in growth medium (F-12K, supplemented with 10% 
FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin) was used as selection pressure to isolate 
cells that took up the plasmid. The growth media in the dishes was exchanged with new media 
containing geneticin (500 µg/ml) once in every 3 days, for ten days. Single discrete colonies were 
selected at the end of ten day period by placing clonal rings on top of the colonies. Cells from 
various colonies were trypsinized and transferred into individual wells of 24-well plates 
containing 500 µl of media and geneticin. The level of expression of the mutant receptors in CHO 
cells was determined by performing an intact whole cell [
3
H]NMS binding assay (see section 2.5 
“Receptor binding assays”). Three colonies with the highest receptor expression as evident from 
the binding assay data were grown in T25 flasks and then stepped up into a T75 flask. After 
attaining confluence in a T75 flask, the stable cells were frozen in cryo vials with 5% DMSO in 
the vapor phase of liquid nitrogen and were revived in growth medium.  
CHO cells stably expressing one of the subtypes of muscarinic receptors (M1-M5), M1 del 
276-282 or M1 del 447-459 were passed a minimum of three times before use in experiments and 
were not passed more than twenty times. For experiments, CHO cells stably expressing individual 
muscarinic receptors (M1-M5), M1 del 276-282 or M1 del 447-459 were plated into 24-well plates 
at a density of 1.65 x 10
5
 cells per well in growth medium (500 µl). Cells were then maintained in 
a humidified incubator set at 37 
o
C in an atmosphere of 5% CO2 /95% air for 24 h, at which time 
the medium in each well of each plate was exchanged for fresh growth medium (500 µl). The 
cells were then maintained in the humidified incubator for an additional 24 h (48 h total) before 
conducting experiments.   
2.4 Receptor trafficking assays 
2.4.1 Receptor internalization assay 
 CHO cells stably expressing one of the subtypes of muscarinic receptor or mutant M1 
receptors were plated in 24-well plates as described above in section 2.3 “Cell culture”. Cells 
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were washed thrice with F-12K to remove serum and then incubated with F-12K containing 
saturating concentration of muscarinic agonist carbachol (1 mM) for different time periods (6 
wells for each time point) in a humidified incubator set at 37 
o
C in an atmosphere of 5% 
CO2/95% air. Carbachol-induced internalization of muscarinic receptor subtypes or mutant M1 
receptors plateaued or nearly plateaued after 4 h of treatment with carbachol (1 mM). Hence, the 
time periods (0 to 4 h) before plateau is reached is used in the internalization experiments. 
Following carbachol treatment, cells were washed extensively on ice thrice with ice-cold PBS. 
Intact, whole cell binding assays were then performed using a single concentration (1.6 nM) of 
the membrane impermeable muscarinic receptor selective radioligand [
3
H]N-metylscopolamine as 
described below in section 2.5 “Receptor binding assays”. Specific [
3
H]NMS binding is used to 
determine the amount of receptor expressed on the cell surface. 
2.4.2 Receptor recycling assay 
 CHO cells stably expressing one of the subtypes of muscarinic receptor or mutant M1 
receptors were plated in 24-well plates (60 wells) as described above in section 2.3 “Cell culture”. 
On the day of the experiment, plates were divided into two equal groups (30 wells per group) and 
cells were washed thrice with F-12K (prewarmed to 37 
o
C) to remove serum. Following the wash 
with F-12K, the first group of cells was incubated with F-12K (prewarmed to 37 
o
C) for 1 h in a 
humidified incubator set at 37 
o
C in an atmosphere of 5% CO2/95% air. The first group of cells 
was used to determine the amount of receptor delivered to the plasma membrane in a constitutive 
manner. At the same time, the second group of cells was incubated with F-12K medium 
containing 1 mM carbachol for 1 h in a humidified incubator set at 37 
o
C. This incubation time 
was chosen because it was the minimal time necessary to obtain maximal or nearly maximal 
receptor internalization for all five subtypes of receptor and mutant M1 receptors. The second 
group of cells was used to measure the amount of constitutive receptor plasma membrane 
delivery plus recycled receptor. After the 1 h incubation period, both groups of cells were washed 
thrice with F-12K (3 x 500 µl) on ice. This wash was conducted on ice to halt receptor 
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trafficking. Cells from both groups were incubated with cyclized BCM (50 nM) for 5 min in a 
humidified incubator set at 37 
o
C. BCM (10 µM) was cyclized in PBS during a 30 min incubation 
at 37 
o
C. The half-time for BCM cyclization is 2.5 min at 37 
o
C, thus a 30 min incubation is 
adequate to ensure complete cyclization of BCM to its membrane-impermeable aziridinium form 
(Gill and Rang, 1966). Cells were washed on ice with F-12K (3 x 500 µl) to remove BCM and 
then incubated for various periods of time for up to 90 min (6 wells for each time point in 
untreated and carbachol-treated plates) in a humidified incubator set at 37 
o
C. Cells were then 
washed with ice-cold PBS (3 x 500 µl) and the amount of receptor expressed on the plasma 
membrane was determined using intact, whole cell [
3
H]NMS binding assays as described below 
in section 2.5 “Receptor binding assays”.   
As a control, 12 wells of a 24-well plate were plated at the same time as experimental 
plates. Each well of the control plate was washed with F-12K (3 x 500 µl) to remove serum and 
then incubated in the absence (6 wells) or presence of carbachol (1 mM; 6 wells) for 1 h in an 
incubator set at 37 
o
C in an atmosphere of 5% CO2/95% air. Each well was washed with ice-cold 
PBS (3 x 500 µl) and then used in intact, whole cell [
3
H]NMS binding assays. The specific 
[
3
H]NMS binding of untreated wells was used to normalize specific binding of experimental 
plates. The specific [
3
H]NMS binding of carbachol treated wells was used to determine how 
much internalization occurred during the 1 h treatment with carbachol.      
2.4.3 Receptor downregulation assay 
CHO cells stably expressing one of the subtypes of muscarinic receptor or mutant M1 
receptors were plated in a 24-well plate as described above under section 2.3 “Cell culture”. 
Plates were divided into two equal groups (12 wells per group) and cells were washed with F-12K 
(3 x 500 µl) to remove serum. The first group of cells was used as a control. This group of cells 
was incubated with F-12K (preheated to 37 
o
C) for 24 h in a humidified incubator set at 37 °C 
and in an atmosphere of 5% CO2/95% air. The second group of cells was incubated with F-12K 
medium containing 1 mM carbachol for 24 h to induce receptor downregulation. This incubation 
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time was chosen because muscarinic receptor downregulation is a slow process that requires 
approximately 24 h for a substantial loss of receptor to be observed (Shockley et al., 1997). Cells 
from both groups were washed extensively on ice with ice-cold PBS (3 x 500 µl). Intact, whole 
cell binding assays were then performed using a single concentration of [
3
H]NMS (6 wells in 
untreated and carbachol treated plates) to determine the amount of plasma membrane expressed 
receptor. To determine the total amount of muscarinic receptor in CHO cells, intact, whole cell 
binding assays using a single concentration of [
3
H]QNB (6 wells in untreated and carbachol 
treated plates) were also performed as described below in section 2.5 “Receptor binding assays.”   
2.4.4 Downregulation assay in the presence of inhibitors 
CHO cells stably expressing each subtype of muscarinic receptor were plated into 24-
well plates as described above in section 2.3 “Cell culture”. On the day of the experiment, cells 
were divided into two equal groups: control and carbachol-treatment groups. The control group 
was treated with vehicle, proteasomal inhibitors (PSI, MG-132, lactacystin) or lysosomal 
inhibitors (NH4Cl, E-64-d) for 24.5 h. The carbachol treatment group was treated with vehicle, 
proteasomal or lysosomal inhibitors for 30 minutes, following which carbachol (1 mM) is added 
and the cells were allowed to incubate with carbachol in the continued presence of vehicle, 
proteasomal or lysosomal inhibitors for 24 hours. Cells from both groups were washed 
extensively on ice with ice-cold PBS (3 x 500 μl) and then used in intact, whole cell binding 
assays using a single concentration of the membrane permeable radioligand [
3
H]QNB (1.2 nM) 
(see section 2.5 “Receptor binding assays”). To get an estimate of receptor downregulation, 
specific [
3
H]QNB binding in cells treated with carbachol in the presence of inhibitor/vehicle was 
divided by the specific binding obtained in cells treated with the inhibitor/vehicle alone, and 
subtracted from 100. The significance of differences between the effects of these inhibitors on 
carbachol-induced downregulation was determined using a one-way ANOVA and Dunnett’s post 




2.4.5 Time-course downregulation assay  
CHO cells expressing each muscarinic receptor subtype were plated into 24-well plates as 
described above in section 2.3 “Cell culture”. Cells were washed three times with 500 µl of F-
12K medium to remove serum and then incubated with carbachol (1 mM) in F-12K medium for 
various time intervals up to 24 hours in a humidified CO2 incubator. Cells were washed 
extensively to remove carbachol (3 x 500 μl PBS) and then used in intact, whole cell [
3
H]QNB 
binding assays as described below in section 2.5 “Receptor binding assays”.  
2.4.6 Assay to determine the potency of carbachol-induced downregulation  
CHO cells expressing a subtype of muscarinic receptor were plated into 24-well plates as 
described above in section 2.3 “Cell culture”. Cells were then treated with equally spaced 
concentrations of carbachol for 7 or 24 hours. Cells were washed extensively to remove carbachol 
(3 washes x 500 μl PBS) and then used in intact, whole cell [
3
H]QNB binding assays as described 
below in section 2.5 “Receptor binding assays”. The concentration of carbachol eliciting half-
maximal response (downregulation) EC50 was estimated using non-linear regression analysis 
(GraphPad Prism, ver. 5.01; San Diego, CA). 
2.5 Receptor binding assays 
Intact, whole cell binding assays were performed using either a single concentration of 
[
3
H]NMS (1.6 nM) or [
3
H]QNB (1.2 nM). The plasma membrane expressed muscarinic receptor 
was quantified using [
3
H]NMS and the total muscarinic receptor expressed was measured using 
[
3
H]QNB. 1.6 nM [
3
H]NMS should occupy approximately 86%, 72%, 84%, 94% and 60% of 
human M1, M2, M3, M4 and M5 receptors, respectively (Ehlert et al., 1996) while 1.2 nM 
[
3
H]QNB should occupy approximately 97%, 98%, 93%, 97% and 96% of human muscarinic M1, 
M2, M3, M4 and M5 receptors, respectively (Bolden et al., 1992). A control was used in each assay 





binding in untreated CHO cells expressing a particular receptor subtype. All other binding data 
from each assay was divided by the control binding and then reported as percent of control. 
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H]QNB were accounted for by this 
transformation. 




H]QNB in the absence (three 
wells for each time point; total binding) and presence (three wells for each time point; nonspecific 
binding) of atropine (10 µM) in 500 µl binding buffer (25 mM HEPES, 113 mM NaCl, 6 mM 
dextrose, 3 mM CaCl2, 3 mM KCl, 2 mM MgSO4, 1 mM NaH2PO4, pH 7.4) for either one h 
([
3








H]QNB was then removed by 
rapidly and gently washing cells with ice-cold PBS (2 x 1 ml). The cells were solubilized with 
500 µl of NaOH (0.25 N) and neutralized with 70 µl of HCl (2.5 N) and pipetted into scintillation 
vials (Griffin et al., 2003). 5 ml of scintiverse BD cocktail was added to the vials and counted 
using a Beckman LS 6500 scintillation counter.  
 BCA protein assay was performed to determine the average amount of protein expressed 
in CHO cells for each radioligand binding assay performed. Three wells of a 24-well plate were 
plated at the same time as experimental plates as described in section 2.3 “Cell culture”. Cells 
were treated the same as the cells in each experiment performed and then cells were washed two 
times with 500 µl mannitol wash buffer (0.29 M mannitol, 0.01 M Tris, 0.5 mM Ca(NO3)2, pH 
7.4) (Goldschmidt and Kimelberg, 1989). The protein concentration was determined for each well 
using the bicinchoninic acid (BCA) protein assay kit following manufacturer’s protocol. 
2.5.1 Filtration receptor binding assays 
 To verify if BCM irreversibly binds muscarinic receptors, CHO M5 cells were plated (5 x 
10
6
 cells/plate) in six 10-cm dishes in growth medium (15 ml, see section 2.3 “Cell culture”). The 
very next day, cells were washed three times with F-12K (15 ml) to remove serum. Five of the six 
plates were incubated with cyclized BCM (50 nM) in F-12K (15 ml) for 5 min at 37 
o
C. The sixth 
plate was incubated in F-12K for 5 min at 37 
o
C. Following the incubation period, cells on each 
plate were rapidly washed (3 times, 15 ml) with ice-cold PBS to remove unbound BCM. Cells 
were then incubated for 5 min at room temperature with 5 ml hypotonic buffer (1 mM Tris-HCl, 1 
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mM EGTA, 1 mM MgCl2, 120 mM sucrose, pH 7.6) (Chang et al., 1981). Cells were scraped 
from plates and transferred into individual tubes (15 ml conical), then homogenized using a 
Tissue-Tearor
TM
 on setting five (15 s). The untreated homogenate was retained on ice. The BCM 
treated homogenates were incubated in a humidified incubator set at 37 
o
C, 5% CO2/95% air for 
0, 15, 30, 60 or 90 min, then retained on ice. Aliquots of homogenates (100 µl) were then 
incubated in 12 x 75 mm polypropylene tubes with [
3
H]NMS (1.6 nM) in binding buffer (see 
section 2.5 “Receptor binding assays”, 400 µl) in the absence (3 tubes, total binding) and 
presence (3 tubes, nonspecific binding) of atropine (10 µM) for 1 h at 4 
o
C with constant shaking. 
Bound [
3
H]NMS was trapped on Whatman glass-fiber filters using a cell harvester (Brandel, 
Gaithersburg, MD). The filters were washed three times with approximately 3 ml of ice-cold 
saline (0.9%) each wash. The assay was repeated twice. 
To verify that [
3
H]QNB permeates intracellular compartments containing muscarinic 
receptor in intact, whole CHO cells, CHO M1 cells were plated (5 x 10
6
 cells/plate) in two 10-cm 
dishes in growth medium (15 ml, see Section 2.3 “Cell culture”). The very next day, cells were 
washed three times with sterile F-12K (15 ml) to remove serum. Plates were then incubated for 
24 h in a humidified incubator set at 37 
o
C in an atmosphere of 5% CO2/95% air in the absence 
(one plate) and presence (one plate) of carbachol (1 mM). Cells on each plate were washed (3 
times, 15 ml) with ice-cold PBS to remove carbachol and then incubated for 5 min at room 
temperature with hypotonic buffer (5 ml). Following the incubation in hypotonic buffer, cells 
were scraped from plates and transferred into individual tubes (15 ml conical), then homogenized 
using a Tissue-Tearor
TM
 on setting five (15 s). The homogenates were pelleted (100,000 x g, 1 h) 
and resuspended in 1 ml binding buffer (see section 2.5 “Receptor binding assays”) containing 
protease inhibitor. Aliquots of homogenates (100 µl) were then incubated in 12 x 75 mm 
polypropylene tubes with [
3
H]QNB (1.6 nM) in binding buffer (400 µl) in the absence (3 tubes, 
total binding) and presence (3 tubes, nonspecific binding) of atropine (10 µM) for 6 h at 4 
o
C with 
constant shaking. Bound [
3
H]QNB was trapped on Whatman glass-fiber filters using a cell 
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harvester (Brandel, Gaithersburg, MD). The filters were washed three times with approximately 3 
ml of ice-cold saline (0.9%) each wash. The assay was repeated twice. 
2.5.2 Saturation binding assays 
Saturation binding assay was conducted on CHO cells stably expressing M1 del 276-282 
or M1 del 447-459 receptors to estimate the equilibrium dissociation constant (KD) of the 
radioligand [
3
H]NMS for the mutant receptors. CHO cells stably expressing the mutant M1 
receptors were plated at a density of 1.65 x 10
5
 cells/well. The following day, the media in the 
wells was exchanged with fresh F-12K media. The very next day, the cells were washed three 
times with ice-cold PBS to remove serum. 400 µl of binding buffer was added to non-specific 
wells while 450 µl of binding buffer was added to the total wells. 50 µl of 10 µM atropine was 
added to the non-specific wells. Then 50 µl of geographically spaced concentrations of the 
[
3
H]NMS was added to both the total and nonspecific wells and incubated at 4 
o
C for 2 hours to 
equilibrate. The cells were then washed twice with 1 ml PBS to get rid of unbound ligands and 
solubilized by incubation with 0.25N NaOH for 30 minutes. 70 µl of 2.5N HCl was added to 
neutralize the solubilized cells containing NaOH. The neutralized extracts were transferred into 
scintillation vials. 5 ml of scintiverse was added to the scintillation vials and radioactivity was 
counted using a Beckman LS 6500 scintillation counter. 
2.6 Phosphoinositide hydrolysis assays 
 Phosphoinositide hydrolysis assays were conducted on CHO cells stably expressing the 
wild-type or mutant M1 receptors as described previously (Sawyer et al., 2006). CHO cells stably 
expressing the wild-type or mutant M1 receptors were washed (3 x 500 µl) with F-12K medium to 
remove serum and then incubated with 0.2 µM [
3
H]myo-inositol (PerkinElmer, Boston, MA) in 
F-12K (500 µl) for 18 h in a humidified incubator. The cells were washed the following day with 
F-12K (2 x 500 µl) to remove unincorporated inositol with 10 min incubation in a humidified 
incubator between each wash. On the third wash, cells were washed with F-12K (270 µl) 
containing LiCl (10 mM). The washed cells were then incubated with F-12K (300 µl) containing 
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LiCl (10 mM) and geometrically spaced concentrations of carbachol (0.5 log unit) for 30 min in a 
humidified incubator at 37 
o
C in an atmosphere of 5% CO2/95% air. The medium was aspirated 
after the 30 minute incubation period. The cells were incubated on ice for 15 min with ice-cold 
5% perchloroacetic acid PCA (200 µl). 0.525 M KOH in 10 mM Tris HCl (360 µl) was added to 
each well and the cells were incubated for an additional 15 min on ice. The neutralized extracts 
(approximately 565 µl) were transferred immediately into 1.5-ml microcentrifuge tubes and each 
well was washed with 25 mM Tris HCl (400 µl), pH 7.4. Each wash was added to the 
corresponding microcentrifuge tube. The tubes were centrifuged at 3000 x g for 10 min to pellet 
cell debris. The supernatant was transferred to glass tubes containing 25 mM Tris HCl (2 ml), pH 
7.4 and mixed. The mixture was then applied to individual 1 ml Dowex AG 1-X8 (HCL form, 
100-200 mesh) columns. Columns were washed three times with 2 ml water and [
3
H]inositol 
phosphates were eluted after washing using 1 M hydrochloric acid (2.5 ml) into 25-ml 
scintillation vials. 20 ml of scintillation cocktail was added and counted using a Beckman LS 
6500 scintillation counter. 
2.7 Data Analysis 
Significance values (P values) calculated using either Student’s t-test, one-way ANOVA 
with Tukey or Dunnett’s post-hoc test (GraphPad Prism, ver. 5.01; San Diego, CA), are reported 
where appropriate (GraphPad Prism, ver. 5.01; San Diego, CA). Data with a P value < 0.05 was 
considered significant. Estimates of the rate constants for muscarinic M1-M5 receptors or mutant 
M1 receptors internalization were made by fitting data using a single-phase exponential decay 
equation (GraphPad Prism, ver. 5.01; San Diego, CA). Estimates of the rate constants for the 
plasma membrane delivery of muscarinic M1-M5 receptors or mutant M1 receptors in untreated 
and carbachol treated cells were made by fitting data using a single-phase exponential association 









3.1 Characterization of internalization, recycling and downregulation of muscarinic receptors 
3.1.1 Comparison of M1-M5 receptor internalization 
 We investigated the kinetics and extent of agonist-induced internalization of human 
muscarinic M1-M5 receptors. CHO cells expressing M1-M5 receptors were incubated with the 
muscarinic receptor selective agonist carbachol (1 mM) for various times up to four hours and 
then receptor binding at the cell surface was measured using a single concentration of [
3
H]NMS 
(1.6 nM). As shown in Figure 1, the internalization of all five subtypes, as determined by 
decreased specific [
3
H]NMS binding, was consistent with a first-order decay process.   
The rate constants for carbachol-induced internalization of each subtype over the time 
interval of 0 to 4 h are estimated and tabulated (Table 1). M2 receptors internalized quickly and to 
a greater extent, when compared to M1, M3, M4 and M5 receptors. The half-time (t½) for M2 
receptor internalization was 8.6 min and specific [
3
H]NMS binding decreased 87% during the 4 h 
treatment with carbachol (Figure 1B and Table 1). The half-times for the carbachol-induced 
internalization of M1 and M3 receptors were similar (t1/2 = 46.3 min and 35.5 min, respectively), 
but were significantly longer than that for M2 receptors (Figures 1A and C, Table 1). Specific 
[
3
H]NMS binding decreased 45% and 41% in CHO cells expressing M1 and M3 receptors, 
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respectively, during carbachol treatment (Figures 1A and C, Table 1). The half-times for M4 and 
M5 receptor internalization were also similar (t1/2 = 12.8 min and 13.1 min, respectively) and 
significantly longer than that for M2 receptors (Figures 1D and E, Table 1). During the 4 h 
carbachol treatment, specific [
3
H]NMS binding decreased 75% in CHO cells expressing M4 
receptors and 65% in CHO cells expressing M5 receptors (Figures 1D and E, Table 1). Overall, 
we observed subtype-specific differences in the rates and extent of internalization between the 





























































































































































 Figure 1. Internalization of M1-M5 receptors. CHO cells stably expressing M1 (A), M2 (B), M3 
(C), M4 (D) or M5 (E) receptors were incubated with carbachol (1 mM) for various periods of 
time for up to 240 min at 37 
o
C. Cells were then used in intact, whole cell [
3
H]NMS binding 
assays as described in section 2.5 “Receptor binding assays”. Each data point represents the mean 
± S.E.M. of three experiments conducted in triplicate.  
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Table 1: Comparison of specific [
3

























M1 (3) 1395.2 ± 42.5 731.5 ± 34.1 0.015 ± 0.004
h
 54.6 ± 3.4
i
 
M2 (3) 177.6 ± 12.8 23.8 ± 3.0 0.080 ± 0.005
j
 13.0 ± 0.53
k
 
M3 (3) 549.4 ± 42.7 309.3 ± 21.2 0.020 ± 0.002
l
 59.1 ± 1.4
m
 
M4 (3) 439.2 ± 16.3 105.5 ± 5.5 0.054 ± 0.006 24.5 ± 1.6
n
 
M5 (3) 262.6 ± 31.6 84.6 ± 5.0 0.053 ± 0.007 34.8 ± 1.4 
a
 Data from Figure 1. 
b
 Number of experiments is shown in parenthesis. 
c
 Binding observed after 4 h of carbachol treatment. 
d
 The rate constant for internalization was determined by fitting data shown in Figure 1 to a 
single-phase decay equation (see Section 2.7 “Data analysis”). 
e 
The rate constants for carbachol-induced internalization differed significantly across the receptor 
subtypes (p < 0.0001) as determined by one-way ANOVA. 
f 
The plateau for internalization was determined by fitting data shown in Figure 1 to a single-
phase decay equation (see Section 2.7 “Data analysis”). 
g 
The plateaus for carbachol-induced internalization differed significantly across the receptor 
subtypes (p < 0.0001) as determined by one-way ANOVA. 
h 
Tukey post-hoc comparisons indicate that the rate constant (K) of M1 receptors is significantly 
different (p < 0.01) from M2, M4, and M5 receptors. 
i 
Tukey post-hoc comparisons indicate that the plateau of M1 receptors is significantly different 
from M2 (p < 0.001), M3 (p < 0.05), M4 (p < 0.001), and M5 (p < 0.001) receptors. 
j 
Tukey post-hoc comparisons indicate that the rate constant (K) of M2 receptors is significantly 
different (p < 0.01) from M3, M4, and M5 receptors. 
k 
Tukey post-hoc comparisons indicate that the plateau of M2 receptors is significantly different (p 
< 0.001) from M3, M4, and M5 receptors. 
l 
Tukey post-hoc comparisons indicate that the rate constant (K) of M3 receptors is significantly 
different (p < 0.01) from M4 and M5 receptors. 
m
 Tukey post-hoc comparisons indicate that the plateau of M3 receptors is significantly different 
(p < 0.001) from M4, and M5 receptors. 
n
 Tukey post-hoc comparisons indicate that the plateau of M4 receptors is significantly different 










3.1.2 Comparison of recycling of M1-M5 receptors  
 The assay for receptor recycling in CHO cells consisted of three sequential phases: 1) 
incubation of cells with carbachol (1 mM, 1 hr) followed by washing, 2) treatment with BCM 
followed by washing, and 3) measurement of the binding of [
3
H]NMS (1.6 nM) at various times 
up to 90 min. An increase in phase 3 binding in response to phase 1 carbachol treatment was 
defined as recycling. Control cells received no carbachol during phase 1.   
BCM is an irreversible muscarinic receptor selective antagonist that alkylates M1-M5 
receptors. To ensure selective alkylation of plasma membrane expressed receptor, BCM was 
cyclized at 37 
o
C for 30 min, which results in a 99.99% conversion of the parent mustard to a 
membrane impermeable quaternary aziridinium ion (Gill and Rang, 1966). CHO cells stably 
expressing M3 receptors were also incubated with increasing concentrations of cyclized BCM (10 
nM, 50 nM, and 100 nM) for either 5, 10 or 20 min (Figure 2 and 3). From these data, it was 
determined that a 5 min treatment with 50 nM BCM was adequate to alkylate approximately 95% 
of plasma membrane expressed M3 receptor (Figure 3). Since a majority of M3 receptors were 
alkylated using these conditions, CHO cells expressing any of the muscarinic receptors were 
incubated at 37 
o
C for 5 min with BCM (50 nM) in phase 2 of recycling experiments. 
Additionally, this short treatment with BCM should minimize the amount of receptor trafficking 
to the plasma membrane during the alkylation phase (phase 2) of recycling experiments. 
Intact, whole cell [
3
H]NMS binding assays (see section 2.5 “Receptor binding assays”) 
were performed on untreated and BCM treated CHO cells expressing M1-M5 receptors. When 
compared to untreated cells, specific [
3
H]NMS binding in BCM treated cells (5 min, 50 nM) 
expressing M1, M2, M3, M4 and M5 receptors decreased 90.4 ± 1.8%, 93.9 ± 1.0%, 97.0 ± 0.3%, 
94.3 ± 0.7% and 85.4 ± 2.7%, respectively (Figure 3).  
From our preliminary studies, we found that M5 receptors had the greatest extent of 
recycling (Figure 4E and Table 2). Hence, we performed filtration binding assays (see section 
2.5.1 “Filtration receptor binding assays”) on homogenates of untreated and BCM treated CHO 
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cells expressing M5 receptors to prove that BCM irreversibly alkylates muscarinic receptors. 
Intact, whole CHO M5 cells were incubated at 37 
o
C for 5 min in the absence (control) and 
presence of cyclized BCM (50 nM). Cells were washed and homogenized and the untreated 
homogenate was retained on ice. The BCM treated homogenates were incubated for 0, 15, 30, 60 
and 90 min at 37 
o
C. 5 min BCM treatment caused a 82% reduction in specific [
3
H]NMS binding 
and a similar reduction was observed after 15 (83%), 30 (82%), 60 (84%) and 90 (85%) min 
incubations at 37 
o
C (data not shown). These data indicate that BCM irreversibly alkylates the 
plasma membrane expressed M5 receptor under conditions similar to those used in recycling 
assays. Presumably, BCM irreversibly alkylates M1-M4 receptors in recycling assays as well. 
 In CHO cells expressing the muscarinic M2 receptor, 1 h carbachol treatment (1 mM) 
caused a 79% reduction in specific [
3
H]NMS binding (Table 2). After BCM alkylation (50 nM, 5 
min), the initial rate of recovery of [
3
H]NMS binding in CHO cells expressing the M2 receptor 
was comparable in untreated and carbachol-treated cells, indicating no significant recycling 
(Figure 4B and Table 2). 
 Unlike the M2 receptor, M1, M3, M4, and M5 receptors recycled after carbachol-induced 
internalization, albeit at different rates and to different extents. When expressed relative to 
control, the initial rate of recycling was 2.5-, 3.8-, 3.1- and 8.9-fold greater in carbachol treated 
cells expressing M1, M3, M4 and M5 receptors, respectively. The corresponding maximal 
increases in binding at 90 min were 1.4-, 1.6-, 1.4- and 3.5-fold respectively. These data are 






































































Figure 2. BCM alkylation of M3 receptors. CHO cells stably expressing M3 receptors were treated 
with either 10 nM or 100 nM cyclized BCM for 10 or 20 minutes. After extensive washing, intact 
whole cell binding assays using [
3
H]NMS (1.6 nM) were performed as described in section 2.5 
“Receptor binding assays”. Each bar represents a single experiment conducted in triplicate. 



































Figure 3. BCM alkylation of M1-M5 receptors. CHO cells stably expressing either muscarinic M1, 
M2, M3, M4 or M5 receptors were treated with cyclized (see section 2.4.2 “Receptor recycling 
assay”) BCM (50 nM) for 5 min at 37
o
C. After extensive washing, intact whole cell [
3
H]NMS 
binding assays were performed as described in section 2.5 “Receptor binding assays”. Each bar 





















































































































































Figure 4. Recycling of M1-M5 receptors. CHO cells stably expressing M1 (A), M2 (B), M3 (C), M4 
(D) or M5 (E) receptors were incubated with () or without () carbachol for 1 h. Cells were 
then washed and treated with cyclized BCM (50 nM) for 5 min as described in section 2.4.2 
“Receptor recycling assay”. Cells were then incubated for various periods of time for up to 90 
minutes at 37 
o
C and then used in intact, whole cell [
3
H]NMS binding assays as described in 
section 2.5 “Receptor binding assays”. Each data point represents the mean ± S.E.M. of three to 




Table 2:  Comparison of the recovery of specific [
3
H]NMS binding for M1-M5 receptors in 






















(% of control) 
M1 (5) 
   Untreated 
   1 h 
 
 
262.8 ± 42.7 
 









   Untreated 
   1 h 
 
 
204.9 ± 3.0 
 
0.28 ± 0.03 
0.41 ± 0.03 
 
12.1 ± 0.6 
14.2 ± 0.1 
M3 (3) 
   Untreated 
   1 h 
 
 
186.4 ± 27.4 
 










   Untreated 
   1 h 
 
 
364.2 ± 23.0 
 










   Untreated 
   1 h 
 
 
96.1 ± 2.1 
 










 Data from Figure 4.  
b
 Number of experiments are shown in parenthesis and the duration of carbachol treatment (1 
mM) is indicated.   
c
 The amount of receptor internalized during carbachol treatment was calculated by subtracting 
specific [
3
H]NMS binding for carbachol treated control cells from that obtained for untreated 
control cells (see section 2.4.2, “Receptor recycling assay”). 
d
 The initial rate was determined for untreated and carbachol treated cells by fitting data shown in 
Figure 4 to a single-phase association equation (see section 2.7, “Data analysis”).  
e
 Recovery of specific [
3
H]NMS binding was calculated by subtracting specific binding at 0 min 
after BCM treatment from that at 90 min after BCM treatment. 
f  
Significantly different from untreated cells (P < 0.05) as determined using a paired Student’s t 















3.1.3 Comparison of M1-M5 receptor downregulation              
[
3
H]QNB is a membrane permeable muscarinic receptor selective antagonist and binds to 
both the cell surface and intracellular muscarinic receptors. Hence [
3
H]QNB binding was used to 
determine the total amount of muscarinic receptors expressed in CHO cells. In the current 
investigation, [
3
H]QNB was used to assess the change in total M1-M5 receptor expressed in intact, 
whole CHO cells after 24 h carbachol treatment (i.e., receptor downregulation) (see section 2.4.3 
“Receptor downregulation assay”). To determine whether [
3
H]QNB can permeate intracellular 
compartments containing muscarinic receptors, CHO M1 cells were incubated in the absence and 
presence of carbachol (1 mM) for 24 h. Untreated and carbachol-treated cells were ruptured using 
a hypotonic buffer and the resulting membranes were washed and pelleted. Untreated and 
carbachol treated membranes were then used in [
3
H]QNB binding assays as described in section 
2.5.1 “Filtration receptor binding assays”. We found that 24 h carbachol treatment caused a 78% 
reduction in specific [
3
H]QNB binding in carbachol treated membranes compared to untreated 
membranes. This reduction was comparable to that observed in intact, whole cell [
3
H]QNB 
binding assays conducted on CHO cells expressing M1 receptors after 24 h carbachol treatment (1 
mM) (see Figure 5A and Table 3). These data suggest that [
3
H]QNB permeates intracellular 
compartments in intact, whole CHO cells. Consequently, intact, whole cell binding assays were 
used to measure M1-M5 receptor downregulation elicited to 24 h carbachol treatment. 
In downregulation assays, CHO cells expressing M1-M5 receptors were incubated with 
carbachol (1 mM) for 24 h. Residual receptors were measured using a single concentration of 
[
3
H]QNB (see section 2.5 “Receptor binding assays”). Following carbachol treatment, specific 
[
3
H]QNB binding in CHO cells expressing M1, M2, M3, M4 and M5 receptors decreased by 72.2 ± 




H]NMS binding in intact, whole CHO cells expressing M1-M5 receptors after 
24 h of carbachol treatment (1 mM) was also determined. In CHO cells expressing M1, M2, M3, 
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M4 and M5 receptors, specific [
3
H]NMS binding decreased 86.6 ± 1.6%, 84.3 ± 0.6%, 63.4 ± 
1.5%, 79.9 ± 0.9% and 75.7 ± 2.2%, respectively (Figure 5 and Table 2). When comparing these 
[
3
H]NMS binding data with the data in Figure 4, it can be seen that the loss of cell surface M1, M3 
and M5 receptors consists of two components. A rapid component occurs during a short-term 
treatment with carbachol, and is nearly complete in approximately 4.5 half-times (1-3.5 h) (Figure 
1A, C, and E). Longer treatment with carbachol (24 h), however, caused a further loss of M1, M3 
and M5 receptors (Figure 5A, C, and E). This slower component was not apparent with M2 and 



































































































































































































Carbachol treated (1 mM)
Figure 5. Downregulation of M1-M5 receptors. CHO cells stably expressing M1 (A), M2 (B), M3 
(C), M4 (D) or M5 (E) receptors were incubated in the absence (open bars) and presence (closed 
bars) of carbachol (1 mM) for 24 h at 37 
o
C. Cells were washed and then used in intact, whole 




H]QNB as described in section 2.5 “Receptor 








H]QNB binding for M1-M5 receptors in 






































  Untreated 
  24 h 
 
748.5 ± 109.2 







808.1 ± 116.7 







  Untreated 
  24 h 
 
74.9 ± 8.3 







109.8 ± 2.3 
64.9 ± 1.4 
 
 
59.1 ± 0.1 
M3 (3) 
  Untreated 
  24 h 
 
471.0 ± 45.9 







425.6 ± 31.1 
227.2 ± 13.4 
 
 
53.5 ± 2.0 
M4 (3) 
  Untreated 
  24 h 
 
428.2 ± 30.3 
86.0 ± 8.1 
 
 
20.1 ± 0.9 
 
364.4 ± 22.6 
164.6 ± 11.5 
 
 
45.1 ± 0.8 
M5 (3) 
  Untreated 
  24 h 
 
195.4 ± 12.1 
47.0 ± 2.5 
 
 
24.3 ± 2.2 
 
237.1 ± 20.0 
115.9 ± 10.0 
 
 
50.0 ± 7.6 
a
 Data from Figure 5. 
b
 Number of experiments are shown in parenthesis. 
c
 The specific [
3
H]NMS binding remaining after 24 h carbachol treatment (1 mM) differed 
significantly across the receptor subtypes (p < 0.0001) as determined by one-way ANOVA. 
d
 The specific [
3
H]QNB binding remaining after 24 h carbachol treatment (1 mM) differed 
significantly across the receptor subtypes (p < 0.01) as determined by one-way ANOVA. 
e 
Tukey post-hoc comparisons indicate that the [
3
H]NMS binding remaining in CHO M1 cells is 
significantly different from M3 (p < 0.001) and M5 (p < 0.01) receptor CHO cells. 
f 
Tukey post-hoc comparisons indicate that the [
3
H]QNB binding remaining in CHO M1 cells is 
significantly different from M2 (p < 0.01), M3 (p < 0.01) and M5 (p < 0.05) receptor CHO cells. 
g
 Tukey post-hoc comparisons indicate that the [
3
H]NMS binding remaining in CHO M2 cells is 
significantly different from M3 (p < 0.001) and M5 (p < 0.05) receptor CHO cells. 
h
 Tukey post-hoc comparisons indicate that the [
3
H]NMS binding remaining in CHO M3 cells is 









3.2 Characterization of effect of proteasomal and lysosomal inhibitors on the downregulation of 
M1-M5 receptors 
3.2.1 Comparison of the extent of carbachol-induced downregulation for various times of 
incubation with carbachol (1 mM) 
We wanted to determine how the specific [
3
H]QNB binding of CHO cells expressing 
muscarinic receptors individually change in response to increasing times of incubation with 
carbachol. CHO cells expressing M1-M5 receptors individually were treated with carbachol (1 
mM) for various periods of time and then intact whole cell [
3
H]QNB binding assay (see section 
2.4.5 “Time-course downregulation assay”) was performed to measure the total amount of 
muscarinic receptors. Changes in [
3
H]QNB binding is a measure of change in total amount of 
receptors. The decrease in [
3
H]QNB binding in response to carbachol (1 mM) was time-
dependent. As seen in figure 6A, over a 24 h treatment with carbachol (1 mM) a significant loss 
in specific [
3
H]QNB binding was observed. This loss in [
3
H]QNB binding represents the amount 
of M1 receptors degraded (downregulated) in response to long-term carbachol treatment and at 24 
h, more than 70% of M1 receptors expressed were degraded. For M2 and M4 receptors loss of 
[
3
H]QNB binding occurred progressively till 6 and 12 hours of continuous exposure to carbachol 
respectively and at 24 h a specific [
3
H]QNB binding of 45 and 32% of control was observed 
(Figure 6B and D). Similarly, the specific [
3
H]QNB binding of M3 receptors decreased in a time-
dependent fashion and a specific [
3
H]QNB binding of 66% of control was measured at 24 h 
(Figure 6C). In the case of M5 receptors, the specific [
3
H]QNB binding decreased rapidly with 
carbachol addition for up to 3 h of carbachol-treatment, following which the specific [
3
H]QNB 
binding declined to 45% of control at 24 h (Figure 6E). In general, a maximal downregulation 
(loss of [
3







































































































































































Figure 6. Time-course downregulation of M1-M5 receptors. CHO cells stably expressing M1 (A), 
M2 (B), M3 (C), M4 (D), or M5 receptors (E) were incubated with carbachol (1 mM) for various 
periods of time for up to 24 h. Cells were washed extensively to remove carbachol and then used 
in intact, whole cell binding assays using a single concentration of [
3
H]QNB (1.2 nM) (section 
2.5 “Receptor binding assay”). Each data point represents the mean ± SEM of three experiments 
conducted in triplicate. 
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3.2.2 Comparison of the potency of carbachol-induced downregulation  
We also determined the potency of carbachol for eliciting muscarinic receptor 
downregulation. As described in section 2.4.6 “Assay to determine the potency of 
downregulation”, we treated CHO cells expressing M1-M5 receptors with equally spaced 
concentrations of carbachol (1- or 0.5-log unit) for 24 h (M1 and M3 receptor expressing cells) or 
7 h (M2, M4 and M5 receptor expressing cells). The duration of treatment was determined from 
data in figure 6. The potency (EC50) of carbachol in downregulating M1, M2, M3, M4 and M5 
receptors are respectively, 1.1, 2.5, 41, 9.5 and 87 µM respectively. Carbachol is respectively 2, 
37, 9 and 79 folds greater in stimulating downregulation in M1 receptors compared to M2, M3, M4 
and M5 receptors. A carbachol concentration of 1 mM which is at least 10 fold greater than the 
potency of carbachol for downregulating muscarinic receptors was used in downregulation 












































































































































































Figure 7. CHO cells stably expressing M1 (A), M2 (B), M3 (C), M4 (D), or M5 receptors (E) were 
incubated with various concentrations of carbachol. Cells were washed extensively to remove 
carbachol and then used in intact, whole cell binding assays using a single concentration of 
[
3
H]QNB (1.2 nM) as described in section 2.5 “Receptor binding assays”. Each data point 





3.2.3 Comparison of the effect of proteasomal inhibitors on the downregulation of M1-M5 
receptors 
We wanted to determine whether muscarinic receptors are downregulated via a 
proteasomal mechanism. To investigate the potential role of the proteasomes in downregulating 
muscarinic receptors, we determined whether the proteasomal inhibitors PSI, MG-132 and 
lactacystin prevent carbachol-induced downregulation. CHO cells expressing M1-M5 receptors 
individually were treated with various proteasomal inhibitors (PSI, MG-132 and lactacystin) 30 
minutes before addition of carbachol. PSI and MG-132 inhibit the chymotrypsin-like activity of 
20S proteasome catalytic subunit, while lactacystin acts irreversibly on the catalytical subunit of 
20S proteasome inhibiting chymotrypsin and trypsin-like activities (Myung et al., 2001). The 
cells were then treated with carbachol (1 mM) for 24 h in the continued presence of inhibitors. 
Treatment of CHO cells expressing muscarinic receptors with proteasomal inhibitors increased 
[
3
H]QNB binding compared to vehicle controls. For example, treatment of CHO cells expressing 
M1, M2, M3, M4 and M5 receptors with proteasomal inhibitor PSI in the absence of carbachol 
caused respectively 1.3-, 1.7-, 1.1-, 1.5- and 1.5- fold increase in the total receptor binding 
compared to the total binding in the same cells treated with vehicle control (Table 4). The loss of 
specific [
3
H]QNB binding (downregulation) for M1 and M3 receptors were significantly affected 
when the carbachol treatment was performed in the continued presence of proteasomal inhibitors 
PSI, MG-132 and lactacystin (see Figure 8, Table 4). Proteasomal inhibitors MG-132 and 
lactacystin significantly decreased the downregulation of M4 receptors, while proteasomal 
inhibitors PSI and lactacystin had a significant inhibition on the downregulation of M5 receptors 
(see Figure 8, Table 4). There was no reduction in the downregulation of M2 receptors in the 
continued presence of any of the proteasomal inhibitors used in our study. Instead, carbachol-
induced downregulation of M2 receptors increased significantly in the presence of proteasomal 
inhibitors (see Figure 8, Table 4). The inhibition of downregulation of muscarinic receptors by 
proteasomal inhibitors is specific. CHO cells stably expressing M1 receptors were pre-treated 
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with various concentrations of proteasomal inhibitor PSI for 30 minutes and then incubated with 
or without carbachol (1 mM) for 24 h in the continued presence of PSI. The inhibition of 
downregulation of M1 receptors by proteasomal inhibitor PSI increased with increasing 
concentrations of PSI. When CHO cells expressing M1 receptors were treated with 0.05, 0.25, 
0.5, 5 and 15 µM of PSI, we observed 1.5, 18, 57, 59 and 58% of inhibition of downregulation of 































































































































































































































 Figure 8. CHO cells stably expressing M1 (A), M2 (B), M3 (C), M4 (D), or M5 receptors (E) were 
treated with PSI, MG-132, lactacystin or vehicle in the absence and presence of carbachol (1 
mM) as described in section 2.4.4 “Downregulation assay in the presence of inhibitors”. Cells 
were incubated for 24 h and then washed extensively. Washed cells were then used in intact, 
whole cell binding assays using a single concentration of [
3
H]QNB (1.2 nM) (see section 2.5 
“Receptor binding assays”). Each bar represents the mean ± S.E.M. of three or more experiments 






 denotes respectively significant differences (p < 0.001), (p < 0.01) 
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and (p < 0.05) from vehicle treatment as determined using a one-way ANOVA with Dunnett’s 
post-hoc test.  
Table 4: Comparison of the specific [
3
H]QNB binding for M1-M5 receptors in CHO cells 



















M1   
 Untreated  
 24 h Carbachol 
 
 
1073 ± 89 (7) 
 




1527 ± 109 (4) 
 
1586 ± 252 
 
 
1431 ± 179 (3) 
 
1098 ± 165 
 
 
1649 ± 235 (3) 
 
1333 ± 222 
M2  
  Untreated 
  24 h Carbachol 
 
 
233 ± 26 (6) 
 




465 ± 85 (3) 
 
127 ± 28 
 
 
415 ± 64 (3) 
 
146 ± 38 
 
 
404 ± 32 (3) 
 
153 ± 15 
M3  
  Untreated 
  24 h Carbachol 
 
 
851 ± 75 (6) 
 




1002 ± 88 (3) 
 
949 ± 103 
 
 
964 ± 80 (3) 
 
772 ± 74 
 
 
1157 ± 146 (3) 
 
947 ± 64 
M4  
  Untreated 
  24 h Carbachol 
 
 
657 ± 102 (6) 
 




1014 ± 72 (3) 
 
419 ± 26 
 
 
1019 ± 84 (3) 
 
546 ± 74 
 
 
1294 ± 187 (3) 
 
694 ± 85 
M5  
  Untreated 
  24 h Carbachol 
 
 
429 ± 38 (7) 
 




672 ± 66 (4) 
 
638 ± 20 
 
 
626 ± 60 (3) 
 
387 ± 28 
 
 
1039 ± 76 (4) 
 
847 ± 182 
a
 Data from figure 8 
b




3.2.4 Comparison of the effect of lysosomal inhibitors on the downregulation of M1-M5 receptors 
We wanted to determine whether muscarinic receptors are downregulated via a lysosomal 
mechanism. To investigate the potential role of the lysosomes in downregulating muscarinic 
receptors, we determined whether the lysosomal inhibitors NH4Cl and E64-d prevent carbachol-
induced downregulation. CHO cells expressing individually M1-M5 receptors were treated with 
lysosomal inhibitors (NH4Cl and E64-d) 30 minutes prior to addition of carbachol. Following the 
treatment with lysosomal inhibitors, cells were incubated with or without carbachol for 24 h in 
the continued presence of lysosomal inhibitors. The carbachol-dependent percent decrease in the 
specific [
3
H]QNB binding of the cells treated with lysosomal inhibitors (NH4Cl, E-64-d) was 
similar to those cells treated with vehicle control, for M1, M3 and M5 receptors (see Figure 9A,C 
and E). However, carbachol-stimulated downregulation of M2 and M4 receptors was significantly 
decreased when treated with NH4Cl (see Figure 9B and D). Further, the carbachol-stimulated 
downregulation of M2 and M4 receptors remained unchanged in response to E-64-d pretreatment. 
Moreover the inhibition of downregulation of muscarinic receptors by lysosomal inhibitors is 
specific. CHO cells stably expressing M2 receptors were pre-treated with various concentrations 
of lysosomal inhibitor NH4Cl for 30 minutes and then incubated with or without carbachol (1 
mM) for 24 h in the continued presence of NH4Cl. With increasing concentrations of NH4Cl, we 
observed a decrease in M2 receptor downregulation. When CHO cells expressing M2 receptors 
were treated with 0.1, 1 and 10 mM concentrations of NH4Cl, the inhibition of carbachol-induced 





























































































































































































Figure 9. CHO cells stably expressing M1 (A), M2 (B), M3 (C), M4 (D), or M5 receptors (E) were 
treated with NH4Cl, E-64-d or vehicle in the absence and presence of carbachol (1 mM) as 
described in 2.4.4 “Downregulation assay in the presence of inhibitors”. Cells were incubated for 
24 h and then washed extensively. Washed cells were then used in intact, whole cell binding 
assays using a single concentration of [
3
H]QNB (1.2 nM) (see section 2.5 “Receptor binding 
assays”). Each bar represents the mean ± S.E.M. of three or more experiments performed in 
triplicate. * Denotes significant differences from vehicle treated condition (p < 0.05) as 
determined using a one-way ANOVA with Dunnett’s post-hoc test.  
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Table 5: Comparison of the specific [
3
H]QNB binding for M1-M5 receptors in CHO cells 
















M1   
 Untreated  
 24 h Carbachol 
 
 
1028 ± 75 (7) 
 




887 ± 107 (3) 
 
335 ± 66 
 
 
937 ± 78 (4) 
 
344 ± 124 
M2  
  Untreated 
  24 h Carbachol 
 
 
198 ± 31 (6) 
 




314 ± 58 (3) 
 
231 ± 49 
 
 
83 ± 5 (3) 
 
47 ± 2 
M3  
  Untreated 
  24 h Carbachol 
 
 
851 ± 75 (6) 
 




770 ± 71 (3) 
 
484 ± 55 
 
 
809 ± 52 (3) 
 
507 ± 16 
M4  
  Untreated 
  24 h Carbachol 
 
 
657 ± 102 (6) 
 




562 ± 122 (3) 
 
302 ± 23 
 
 
319 ± 48 (3) 
 
131 ± 7 
M5  
  Untreated 
  24 h Carbachol 
 
 
429 ± 38 (7) 
 




300 ± 12 (3) 
 
193 ± 25 
 
 
404 ± 67 (4) 
 
250 ± 67 
 
a
 Data from figure 9 
b





3.3 Characterization of domains in the third intracellular loop and C-terminal tail of M1 receptor 
3.3.1 Effect of deletion of the amino acids within regions of third intracellular loop or C-terminal 
tail on the binding of M1 receptors 
We wanted to determine whether the deletions made in the i3 loop or C terminal tail of 
muscarinic receptors affected the ability of M1 receptors to bind muscarinic receptor antagonist 
[
3
H]NMS. Hence, we made deletions in the i3 loop and C-terminal tail of the M1 receptor using 
site-directed mutagenesis and created CHO cells stably expressing M1 del 276-282 or M1 del 447-
459 receptors. Saturation binding assays were performed and equilibrium dissociation constant 
KD was estimated for CHO cells stably expressing i3 loop or C terminal tail deletion mutants and 
compared with KD value for wild-type M1 receptors. We found that the equilibrium dissociation 
constants for wild-type and mutant receptors were comparable (Figure 10, Table 6) and the 
deletion mutations did not affect the affect the affinity of M1 receptors. 
  








































Figure 10. Effect of deletion of amino acids in the i3 loop or C terminal tail of M1 receptors on 
[
3
H]NMS binding. Intact, whole cell [
3
H]NMS binding  assays were performed on CHO cells 
stably expressing muscarinic M1 del 276-282 or M1 del 447-459 receptors (see section 2.5 
”Receptor binding assays”). Each data point represents the mean ± S.E.M. of two experiments 














M1 wild-type (2) 0.61 ± 0.02
* 
M1 del 276-282 (2) 0.43 ± 0.001 
M1 del 447-459 (2) 0.94 ± 0.06 
* 
adapted from Sawyer et al., 2010 
 
a 
Data from Figure 10. 
b 
Number of experiments are shown in parenthesis. 
c
 KD was determined by fitting data shown in Figure 10 to a non-linear regression equation. 
 
3.3.2 Effect of the deletion of amino acids within regions of third intracellular loop or C-terminal 
tail on the signaling of M1 receptors. 
 We wanted to determine the functional role of mutant receptors. To estimate the 
functional response of the deletion mutants, phosphoinositide hydrolysis assays were performed. 
CHO cells expressing either M1 wild-type, M1 del 276-282 or M1 del 447-459 receptors were 
incubated with [
3
H]myo-inositol for 18h. The cells were stimulated with equally spaced 
concentrations (0.5-log unit) of carbachol for 30 minutes and then [
3
H]inositol phosphates were 
counted. The potency (EC50) and maximal response (Emax) for the wild-type and mutant receptors 
were estimated using a non-linear regression analysis. Deletion of amino acids 276-282 in the i3 
loop region of M1 receptors caused respectively, 3.2- and 1.5- fold increase in the EC50 and Emax 
values compared to wild-type M1 receptors (Figure 11 and Table 7). The EC50 value of M1 del 
447-459 receptors were 5.8 fold greater than that of M1 wild-type receptors, while the Emax value 
of M1 del 447-459 receptors is only 53% of that of wild-type M1 receptors (Figure 11 and Table 
7). From the data obtained, it is clear that the mutant M1 receptors were functional even though 








































Figure 11. The effect of deletion of amino acids within regions of i3 loop or C terminal tail on 
carbachol-mediated phosphoinositide hydrolysis. CHO cells stably expressing muscarinic M1 del 
276-282 or M1 del 447-459 receptors were incubated with 0.2 µM [
3
H]myo-inositol for 18 h and 
then phosphoinositide hydrolysis assay was performed as described in section 2.6 
“Phosphoinositide hydrolysis assays”. Each data point represents the mean ± S.E.M. of three 
experiments conducted in triplicate.  
 










M1 wild-type (3) 5.7 ± 0.2
d
 34508 ± 1784
e
 
M1 del 276-282 (3) 5.2 ± 0.2 51471 ± 3136 
M1 del 447-459 (3) 4.9 ± 0.1 18314 ± 1673 
a 
Data from Figure 11. 
b 
Number of experiments are shown in parenthesis. 
c
 pEC50 and Emax were determined by fitting data shown in Figure 11 to a non-linear regression 
equation. 
d
 significantly different from EC50 of M1 del 276-282 (p < 0.05) and M1 del 447-459 (p < 0.01) 
receptors as determined using a one-way ANOVA with Dunnett’s post-hoc test 
e
 significantly different from Emax of M1 del 276-282 (p < 0.001) and M1 del 447-459 (p < 0.01) 







3.3.3 Comparison of the kinetics and extent of internalization of wild-type and mutant M1 
receptors: 
We determined if the kinetics and extent of agonist-induced internalization of M1 
receptors was affected by deletion mutations introduced in the i3 loop or C-terminal tail. CHO 
cells expressing M1 wild-type receptors, M1 del 276-282 or M1 del 447-459 receptors were 
incubated with the muscarinic receptor selective-agonist carbachol (1 mM) for various times up 
to four h and then receptor binding at the cell surface was measured using [
3
H]NMS (1.6 nM). 
The internalization of all the three receptors (M1 wild-type, M1 del 276-282 and M1 del 447-460 
receptors) were consistent with a single phase exponential decay process (Figure 12). 
The half-time and plateau for M1 wild-type receptor was 46.33 min and 54.58% of 
control respectively. The half time for muscarinic M1 del 276-282 receptor (63.77 min and 
52.43% of control) was nearly1.4 fold greater than that of muscarinic M1 wild-type receptor while 
the plateau of internalization is same as that of wild-type receptor. The half time for muscarinic 
M1 del 447-459 receptor (24.70 min and 55.62 % of control) was 53% of the half-time of 
muscarinic M1 wild-type receptor while the plateau of internalization is same as that of wild-type 
receptor (Figure 12, Table 8). There were no significant differences in the rate constant and 
plateaus of internalization between the wild-type and mutant M1 receptors suggesting that 
carbachol-induced internalization was unaffected by the mutation. This suggests that the agonist-
















































































































Figure 12. Comparison of internalization of wild-type and mutant M1 receptors. CHO cells stably 
expressing muscarinic M1 wild-type (A), M1 del 276-282 (B), or M1 del 447-459 (C) receptors 
were incubated with carbachol (1 mM) for various periods of time for up to 240 min at 37
o
C.  
Cells were then used in intact, whole cell [
3
H]NMS binding assays (see section 2.5 “Receptor 
binding assays”). Each data point represents the mean ± S.E.M. of three experiments conducted 



















Table 8: Comparison of specific [
3
H]NMS binding and rate constants for wild-type and mutant 
















binding in cells 
treated with 














M1 wild-type (3) 1395.2 ± 42.5 731.5 ± 34.1 0.015 ± 0.004 54.58 ± 3.43 
 
M1 del 276-282 (3) 370.7 ± 15.4 200.5 ± 6.7 0.011 ± 0.002 
 
52.43 ± 2.75 
 
M1 del 447-459 (3) 
 
1454.6 ± 72.0 762.4 ± 51.3 0.028 ± 0.005 
 
55.62 ± 1.91 
a 
Data from Figure 12. 
b 
Number of experiments are shown in parenthesis. 
c
 The rate constant for internalization was determined by fitting data shown in Figure 12 to a 
single-phase decay equation. 
d
 The plateau for internalization was determined by fitting data shown in Figure 12 to a single-


















3.3.4 Comparison of the recovery of wild-type and mutant M1 receptors in untreated and 
carbachol-treated cells following incubation with BCM 
 We wanted to determine if recycling of M1 receptors was affected by deletion of domains 
in i3 loop or C-terminal tail. CHO cells stably expressing M1 wild-type, M1 del 276-282 or M1 del 
447-459 receptors were used in recycling assays as described in section 2.4.2 ” Receptor 
recycling assay”. [
3
H]NMS was used to quantitate the amount of receptors delivered to the 
plasma membrane in untreated and carbachol-treated CHO cells. Any difference in the initial rate 
or extent of delivery of muscarinic receptors to the plasma membrane between the untreated and 
carbachol-treated condition would be a proof of recycling. BCM, an irreversible muscarinic 
receptor antagonist was used in recycling assays. CHO cells stably expressing M1 wild-type 
receptors, M1 del 276-282 or M1 del 447-459 receptors were incubated with 50 nM BCM for 5 
min. Nearly, 90.4 ± 1.8%, 92.2 ± 2.3% and 82.4 ± 1.2% of M1 wild-type, M1 del 276-282 and M1 
del 447-459 receptors, respectively were alkylated. 
 In CHO cells expressing M1 wild-type receptors, 1 h carbachol treatment caused a 22% 
decrease in specific [
3
H]NMS binding. The initial rate of recovery of [
3
H]NMS binding in CHO 
cells expressing M1 wild-type receptors was 2.5 ± 0.4 fold greater in carbachol treated cells than 
in untreated cells after BCM alkylation. At 90 min after BCM alkylation, maximal M1 wild-type 
receptor recovery was 1.4-fold greater in carbachol treated cells when compared to untreated cells 
(Figure 13 and Table 9). 
 In CHO cells expressing M1 del 276-282 receptors, 1 h carbachol treatment caused 18% 
decrease in specific [
3
H]NMS binding while 2 h carbachol treatment caused 30% decrease in 
specific [
3
H]NMS binding. In order to achieve a percentile of internalization comparable to 1 h of 
internalization observed in wild-type receptors, we treated CHO cells expressing M1 del 276-282 
receptors for 2 h before performing recycling assays. The initial rate of recovery of [
3
H]NMS 
binding in CHO cells expressing M1 del 276-282 receptors was nearly the same in both carbachol 
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treated and untreated cells. At 90 min after BCM alkylation, maximal M1 del 276-282 receptor 
recovery of carbachol treated cells was similar to that of untreated cells (Figure 13 and Table 9). 
1 h carbachol treatment caused 24% reduction in [
3
H]NMS binding in CHO cells 
expressing M1 del 447-459 receptors. The initial rate of recovery of [
3
H]NMS binding in CHO 
cells expressing M1 del 447-459 receptors was similar in both carbachol treated and untreated 
cells. At 90 min after BCM alkylation, maximal M1 del 447-459 receptor recovery of carbachol 
treated cells was comparable to that of untreated cells (Figure 13 and Table 9). 
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Figure 13. Comparison of  recycling of wild-type and mutant M1 receptors. CHO cells stably 
expressing M1 wild-type (A), M1 del 276-282 (B) or M1 del 447-459 (C) receptors were incubated 
with () or () without carbachol. Cells were then washed and treated with cyclized BCM (50 
nM) for 5 min. Cells were then incubated for various periods of time for up to 90 minutes at 37
o
C 
and then used in intact, whole cell [
3
H]NMS binding assays (see section 2.5 “Receptor binding 




Table 9:  Comparison of the recovery of specific [
3
H]NMS binding for wild-type and mutant M1 





















(% of control) 
M1 wild-type (5) 
   Untreated 
   1 h  
 
 
262.8 ± 42.7 
 









M1 del 276-282 (3) 
   Untreated 
   2 h 
 
 
106.8 ± 10.7 
 
0.99 ± 0.54 
0.67 ± 0.23 
 
11.8 ± 1.7 
15.2 ± 0.4 
M1 del 447-459 (3) 
   Untreated 
   1 h 
 
 
366.8 ± 84.2 
 
1.09 ± 0.46 
1.03 ± 0.29 
 
30.0 ± 3.7 
21.9 ± 1.9 
a
 Data from Figure 13.  
b
 Number of experiments are shown in parenthesis and the duration of carabachol (1 mM) is 
indicated.   
c
 The amount of receptor internalized during carbachol treatment was calculated by subtracting 
specific [
3
H]NMS binding for carbachol treated cells from that for untreated cells. 
d
 The initial rate was determined for untreated and carbachol treated cells by fitting data shown in 
Figure 13 to a single-phase association equation.  
e
 Recovery of specific [
3
H]NMS binding was calculated by subtracting specific binding at 0 min 
after BCM treatment from that at 90 min. 
* Significantly different from untreated cells (P < 0.05) as determined using a paired Student’s t-
test (two-tailed).       
 
3.3.5 Comparison of downregulation of wild-type and mutant M1 receptors 
We determined the downregulation of  M1 del 276-282 and M1 del 447-459 receptors and 
compared with the downregulation of M1 wild-type receptors in CHO cells. CHO cells expressing 
wild-type or mutant M1 receptors were incubated with carbachol (1 mM) for 24 h and then 





H]QNB are membrane-impermeable and membrane-permeable ligands 




H]QNB binding is a 
measure of decrease in cell surface and total muscarinic receptors. Following carbachol treatment, 
specific [
3
H]NMS binding in CHO cells expressing M1 wild-type, M1 del 276-282 and M1 del 
447-459 receptors decreased by 86.6 ± 1.6%, 49.1 ± 2.8% and 23.5 ± 2.3%, respectively. Specific 
[
3
H]QNB binding in CHO cells expressing M1 wild-type, M1 del 276-282 and M1 del 447-459 
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receptors decreased by 72.2 ± 3.6%, 26.4 ± 2.2% and 1.9 ± 11.8% , respectively when incubated 




























































































































Figure 14. Comparison of downregulation of wild-type and mutant M1 receptors. CHO cells 
stably expressing M1 wild-type (A), M1 del 276-282 (B) or M1 del 447-459 (C) receptors were 
incubated in the absence (open bars) and presence (closed bars) of carbachol (1 mM) for 24 h at 
37
o





H]QNB (see section 2.5 “Receptor binding assays”). Each bar represents the mean ± S.E.M. 









H]QNB binding for wild-type and mutant 




































M1 wild-type (3) 
  Untreated 
  24 h 
 
748.5 ± 109.2 
103.2 ± 26.6 
 
 
13.4 ± 1.6 
 
808.1 ± 116.7 
233.0 ± 64.6 
 
 
27.8 ± 3.6 
M1 del 276-282 (3) 
  Untreated 
  24 h 
 
213.4 ± 11.7 







248.7 ± 14.5 






M1 del 447-459 (5) 
  Untreated 
  24 h 
 
447.2 ± 32.6 







799.1 ± 69.2 







 Data from Figure 14. 
b 
Number of experiments is shown in parenthesis. 
c
 Significantly different (P < 0.01) from M1 wild-type receptors as determined by one-way 
ANOVA with Dunnett’s post-hoc test. 
d
 Significantly different (P < 0.01) from M1 wild-type receptors as determined by one-way 









4.1 Characterization of the agonist-dependent internalization, recycling and 
downregulation of muscarinic receptors 
In this investigation, subtype-specific differences in the internalization, recycling and 
downregulation of M1-M5 receptors in CHO cells were observed. Proteins playing a central role 
in the agonist-induced regulation of GPCRs such as GRKs and arrestins are expressed in many 
different cell types to similar levels (Attramadal et al., 1992; Komori et al., 1998; Parruti et al., 
1993; Shenoy and Lefkowitz, 2003) and hence subtype-specific differences in agonist-dependent 
internalization, recycling and downregulation exists in other cell types. These differences were 
unrelated to whether the subtype signaled through Gq/11 (M1, M3 and M5) or Gi/o (M2 and M4), 
suggesting that the subtypes use different mechanisms for internalization, recycling and 
downregulation. Stable CHO cell lines expressing muscarinic receptors individually to different 
levels were used in the study and comparison of rates and extents of internalization were studied. 
Previous studies have shown that the loss of cell surface [
3
H]NMS binding (internalization) for 
carbachol treated cells was independent of the plasma membrane receptor expression in U293 
cells and JEG-3 cells (Lameh et al., 1992; Goldman et al., 1996). Hence our comparisons of the 
internalization of M1-M5 receptors, which express around 1395 ± 43, 178 ± 13, 549 ± 43,  439 ± 
16, 263 ± 32 fmol/ mg of proteins respectively is valid and within the 10 fold range (Table 1). 
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In the current study in CHO cells while M1 and M3 receptors internalized slowly and to a 
small extent, the M4 and M5 receptors internalized to a faster and greater extent (Figure 1). 
Among the five subtypes studied by us, the M2 receptor internalized fastest and greatest of all 
(Figure 1). These observations are generally consistent with those of other investigators working 
on CHO cells (Koenig and Edwardson, 1996; Tsuga et al., 1998a; Sawyer et al., 2006). The rate 
and extent of carbachol-induced muscarinic M5 receptor internalization in CHO cells has not been 
characterized previously.     
Under similar assay conditions in COS-7 cells (i.e., 1 mM carbachol treatment), the half-
times for carbachol-induced M1 and M5 receptor internalization (t½ = 43 min and t½ = 12 min, 
respectively; (Tsuga et al., 1998b)) were comparable to those obtained in the current study. In 
contrast, the half-time for M3 receptor internalization in COS-7 cells (t½ = 11 min) was 31% of 
that observed in our study (Tsuga et al., 1998b). More M1, M3 and M5 receptors internalized  in 
CHO cells (32%, 33% and 63% of control, respectively) than in COS-7 cells (10%, 20% and 25% 
of control, respectively) after 2 h of carbachol treatment (1 mM) (Tsuga et al., 1998b). Tsuga and 
coworkers, (1998b) also determined that 10 µM and 100 µM carbachol treatment elicited 
maximal M2 and M4 receptor internalization, respectively in COS-7 cells. Under these assay 
conditions, the half-times for M2 and M4 receptor internalization in COS-7 cells (t½ = 37 min and 
49 min, respectively) were different than those observed in the present study (t½ = 8.6 min and 
12.8 min, respectively) (Tsuga et al., 1998b). Additionally, M2 and M4 receptors internalized to a 
lesser extent in COS-7 cells (47% and 45% of control, respectively) than in CHO cells (88% and 
77% of control, respectively) after two hours of carbachol treatment (Tsuga et al., 1998b). 
Overall, there are differences in the carbachol-induced internalization of muscarinic receptor 
subtypes in COS-7 cells, when compared to CHO cells. The rank order for the rate of 
internalization in CHO cells observed in our study was M2 > M4 > M5 > M3 > M1 whereas in 
COS-7 cells it was M3 > M5 > M2 > M1 > M4 (Tsuga et al., 1998b). Differences in the rank order 
for internalization of muscarinic receptor subtypes expressed in CHO cells and COS-7 cells could 
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be due to the differences in the levels of expression of arrestins and GRKs in COS-7 cells and 
CHO cells (Menard et al., 1996).       
We observed a significant amount of internalization in CHO cells expressing muscarinic 
receptors when treated with agonist carbachol for 1 hour. The amount of internalization at 1 h of 
carbachol treatment was sufficient to see internalized receptors recycle back to the plasma 
membrane. Additionally, the recycling kinetics was also independent of the amount of receptors 
internalized. Increasing the size of internalized receptor pool available for recycling by increasing 
the incubation time with carbachol had no effect on the rate of recovery, but only increased the 
extent of recovery (Koenig and Edwardson, 1994a). Further, the extent of carbachol treatment did 
not significantly affect the rate of recovery of M2 receptors in HEK293 cells (Roseberry and 
Hosey 1999). In our study, we identified no significant differences between the rate constants for 
recovery in the presence of carbachol when internalization of M5 receptors was increased from 
87.9 fmol/mg of protein (corresponding to 1 hour internalization with 1 mM carbachol) to 111.7 
fmol/mg of protein (corresponding to 3 hour internalization with 1 mM carbachol) (data not 
shown). This observation very clearly indicated that the rate constant for recycling did not depend 
upon the amount of receptors internalized or available to recycle and served as strong evidence in 
validating our comparison of agonist-induced recovery among the five subtypes of muscarinic 
receptors. 
In our recycling experiments, BCM was used for the alkylation phase because it has a 
short half-time for alkylation (t½ = 33 sec). A 5-min incubation with BCM (50 nM) alkylated 85% 
or more of muscarinic M1-M5 receptors expressed on the plasma membrane of CHO cells (see 
Figure 3). It is likely that only a few muscarinic receptors traffic to the plasma membrane of CHO 
cells during this 5 min incubation with BCM. Thus, in recycling experiments for alkylation of 
muscarinic receptors with BCM, an incubation temperature of 37 
o
C was used instead of a 
temperature (e.g., 15 
o
C) that inhibits receptor trafficking. In previous investigations using 
PrBCM mustard (t1/2 for alkylation = 2 min), it was necessary to incubate cells at 15 
o





to inhibit receptor trafficking during the 20 to 30 min incubation with PrBCM (Koenig and 
Edwardson, 1994b; Koenig and Edwardson, 1994a; Koenig and Edwardson, 1996). By using the 
approach in our study, we considerably reduced the time necessary to alkylate a significant 
fraction of plasma membrane expressed muscarinic receptor.    
In cells not exposed to carbachol, trafficking of receptors to the plasma membrane after 
BCM treatment may be from the endoplasmic reticulum, and thus are newly synthesized, or from 
endosomes or both. In previous investigations, pretreatment of cells with protein synthesis 
inhibitor cycloheximide significantly reduced the rate of [
3
H]NMS recovery after irreversibly 
alkylating the cell surface receptors with PrBCM (Koenig and Edwardson, 1994b; Koenig and 
Edwardson, 1994a; Haddad et al., 1995; Koenig and Edwardson, 1996). These data demonstrate 
that a significant fraction of the total receptors that trafficked to the plasma membrane after 
treatment with PrBCM were newly made receptors. Therefore, it is anticipated that newly 
synthesized muscarinic receptor also makes up a significant fraction of the receptor delivered to 
the plasma membrane of CHO cells after BCM treatment in untreated cells. In recycling assays, 
the rank order of the initial rate and extent of receptor delivery after BCM treatment in untreated 
cells is M1 > M4 > M2 = M5 > M3 and M5 = M1 > M4 > M2 > M3, respectively (Table 2 and Figure 
4). 
In carbachol-treated cells (1 mM, 1 h), the initial rate of recovery of [
3
H]NMS binding is 
a measurement of the basal plasma membrane delivery of muscarinic receptors plus the delivery 
of internalized muscarinic receptor that recycle back to the plasma membrane. Thus a difference 
in the rate or extent of recovery of specific [
3
H]NMS binding in carabachol-treated cells versus 
untreated cells would be an indication of muscarinic receptor recycling. Using this approach, it 
was found that the M2 receptor did not recycle and that the rank order of recycling for other 
receptors was M5 > M4 > M3 > M1 (Table 2). The observation that M4 receptors recycled to a 
greater extent than M3 receptors in CHO cells was consistent with the studies performed by 
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Koenig and Edwardson, (1996) using a different approach. The recycling of M1, M2 and M5 
receptors was not determined in their study (Koenig and Edwardson, 1996).  
The downregulation of M1, M2 and M3 receptors observed in our study was comparable 
to that previously observed in CHO cells (Tsuga et al., 1998a; Shockley et al., 1999). Prior to the 
current study, the agonist-induced downregulation of the M5 receptor had not been determined 
and the downregulation of M4 receptor had not been characterized in CHO cells. The 
downregulation of the M1 receptor in U293 cells was 22% of that observed in our study, 
suggesting that cell type may influence the extent of muscarinic receptor downregulation (Lameh 
et al., 1992). In contrast to the difference in M1 receptor downregulation in CHO and U293 cells, 
the downregulation of M4 receptors in AtT-20 cells was comparable to that observed in the 
present study (Lenz et al., 1994). Further in endogenous brain tissue, the total protein levels of 
each of the M1, M2 and M4 receptors in acetylcholineesterase knockout mice were reduced 
approximately 50% compared to the wild type mice suggesting the occurrence of downregulation 
of muscarinic receptors in response to endogenous acetylcholine (Li et al., 2003). 
Treatment with carbachol for 24 h caused a significant reduction in specific [
3
H]NMS 
binding of muscarinic receptors. In CHO cells expressing M2 and M4 receptors, specific [
3
H]NMS 
binding remaining after 24 h carbachol treatment (16% and 20%, respectively) was comparable to 
that observed after 4 h carbachol treatment (13%  and 25%, respectively) (see Tables 1 and 2).  
This observation suggests that the maximal effect of carbachol on the plasma membrane 
expression of M2 and M4 receptors occurs within a relatively short period of time. In contrast, the 
percent specific [
3
H]NMS binding remaining after 24-h carbachol treatment (1 mM) in CHO cells 
expressing muscarinic M1 (13%), M3 (37%) and M5 (24%) receptors was lower than that 
observed after 4 h carbachol treatment (55%, 59% and 35%, respectively) (see Tables 1 and 3). 




H]QNB binding in unstimulated cells were comparable for 
M1-M5 subtypes suggesting that in untreated conditions, most of the muscarinic receptors are 
expressed on the cell surface. This is consistent with microscopic studies performed in striatal 
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dendrites using immunogold labeling technique where most of the muscarinic receptors (about 
89%) were localized to the plasma membrane (Bernard et al., 1999) as well as binding studies 
performed in PC12 cells (Volpicelli et al 2002). 
4.2 Characterization of the effect of proteasomal and lysosomal inhibitors on the 
downregulation of muscarinic receptors 
In this investigation, we observed subtype-specific differences in the mechanisms of 
downregulation. The downregulation of Gq/11 coupled receptors (M1, M3 and M5) was sensitive to 
proteasomal inhibitors. On the other hand, the downregulation of Gi/o coupled M2 receptors was 
inhibited by lysosomal inhibitor NH4Cl. However, the carbachol-stimulated downregulation of 
M4 receptors, which couple with Gi/o proteins was sensitive to both proteasomal and lysosomal 
inhibitors. Hence, the differences in the mechanisms of downregulation in the muscarinic 
receptors were unrelated to the type of G protein they coupled with. Previous findings performed 
in histamine H1 receptors a Gq coupled receptor revealed that the downregulation was inhibited 
by proteasomal inhibitors lactacystin and MG-132 (Hishinuma et al., 2010). The downregulation 
of Gi coupled κ, δ and µ opioid receptors were also sensitive to proteasomal inhibitors and not to 
lysosomal inhibitors (Li et al., 2000; Chaturvedi et al., 2001). This is in agreement with our study 
that the pathway of downregulation was independent of the type of G protein coupled. 
Comparisons of the time-course of internalization of muscarinic receptors to the time-
course of downregulation of muscarinic receptors (Figures 1 and 6) suggest that internalization is 
a pre-requisite for downregulation of muscarinic receptors (Li et al., 2000). The potencies of 
carbachol to elicit downregulation of M2 and M4 receptors (Figure 7) were also similar to the 
potencies of carbachol in causing internalization of these receptors (Tsuga et al., 1998b). This 
clearly suggests that internalization is a preceding step in downregulation of M2 and M4 receptors. 
In our time-course downregulation assays, we observed transient up-regulation of M1 and M3 
receptors after 1 h of carbachol treatment following which downregulation continues. This could 
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be the result of a finite amount of receptor delivery to QNB accessible vesicle from QNB 
insensitive storage vesicle (Volpicelli et al 2002). 
We observed that pretreatment of CHO cells expressing muscarinic receptors with 
proteasomal inhibitors in the absence of carbachol increased the expression of muscarinic 
receptors (Figure 12 and Table 4). In a typical cell, both constitutive degradation and biosynthesis 
of receptors takes place simultaneously. Proteasomal inhibitors might have inhibited the 
constitutive degradation of muscarinic receptors with no effect on the biosynthesis of receptors. 
Hence there is an increase in receptor expression in cells treated with proteasomal inhibitors alone 
when compared to vehicle treated cells. Our findings are consistent with the increased expression 
of δ and µ opioid receptors in HEK293 cells pretreated with proteasomal inhibitors alone 
(Chaturvedi et al., 2001).  
M1, M3 and M5 receptor downregulation was affected by proteasomal inhibitors only, 
while M2 receptor downregulation was inhibited by lysosomal inhibitors only. M4 receptor 
downregulation was affected by both proteasomal and lysosomal inhibitors. This is consistent 
with previous studies where downregulation of some GPCRs are affected by only proteasomal 
inhibitors (Chaturvedi et al., 2001; Hishinuma et al., 2010) while downregulation of few GPCRs 
are inhibited by lysosomal inhibitors only (Marchese and Benovic, 2001). Yet there are a few 
receptors whose downregulation was inhibited by both proteasomal and lysosomal inhibitors (Li 
et al., 2000; Dupre et al., 2003). The lysosomal inhibitor E-64-d did not have any significant 
effect on the downregulation of any of the muscarinic receptor. This might be the result of 
lysosomal enzymes inhibited by E-64-d not taking an active part in degradation of muscarinic 
receptors. Although there are cell-specific differences in the extent of downregulation of 
muscarinic receptors, the mechanisms of downregulation could be similar (Lenz et al., 1994). For 
example, the finding that M4 receptor downregulation in CHO cells is affected by lysosomal 
inhibitor NH4Cl is congruent with the reduction of muscarinic receptor downregulation by NH4Cl 
in NG-108 cells which expresses M4 receptors (Ray and Berman, 1989). No significant effect of 
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the lysosomal inhibitor NH4Cl on the downregulation of M3 receptors expressed in CHO cells is 
also consistent with no effect on the downregulation by NH4Cl in vas deferens (Hiroshi et al., 
1982), which expresses M3 receptors (Silva et al., 1988).  
Proteasomal inhibitors (PSI, MG-132 and lactacystin) significantly increased the 
downregulation of M2 receptors. This is in sharp contrast to the inhibition of M2 receptor 
downregulation in MEF cells by proteasomal inhibitor lactacystin (Mosser et al., 2008). In 
MDCK cells, Shmuel et al (2007) have shown that only a very small fraction of M1 receptors 
colocalize with Rab7 after agonist-stimulation suggesting that there could be pathways alternate 
to the lysosomal pathway for the degradation of M1 receptors. This is consistent with the current 
study where no significant effect of lysosomal inhibitors on the downregulation of M1 receptors 
was observed. Proteasomal inhibitor PSI did not have any inhibitory effect on the downregulation 
of M2 receptors at both shorter and longer incubation times with carbachol. Similarly lysosomal 
inhibitor NH4Cl did not have any inhibitory effect on the downregulation of M1 receptors.  
All of the above results point to a mechanism where the degradation of GPCRs happens 
(lysosomes only, proteasomes only or combination of both). In the first pathway, the degradation 
happens completely in the lysosomes or proteasomes. An example for degradation happening 
completely in lysosomes is agonist-induced downregulation of CXCR4 receptors. The 
downregulation of histamine H1 receptors is completely inhibited by proteasomal inhibitors. In 
the second pathway, one fraction of the receptors is degraded in the lysosomes, while the other in 
the proteasomes. A very good example of this pathway is the agonist-induced downregulation of 
PAFR where the inhibition of proteasomal and lysosomal inhibitors is additive. There is a third 
possibility that the downregulation proceeds initially in the proteasomes where the receptor might 
be digested partially to a radioligand unidentifiable fragment. This protein fragment is then 
transported to the lysosomes where final degradation takes place. This study is the first of its kind 
to study the mechanism of downregulation of muscarinic receptors in a heterologous cell line 
with a battery of proteasomal and lysosomal inhibitors. Proteasomal and lysosomal inhibitors 
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differentially inhibited the downregulation of muscarinic receptors. These differences could be 
due to the variations in sequences between muscarinic receptors. Sequence variations in 
muscarinic receptors are prominent in the third intracellular loop and C-terminal tail region when 
compared to other regions (Hulme et al., 1990). As a result of sequence variations in the 
cytoplasmic regions (i3 loop and C-terminal tail) involved in trafficking, there could be 
differences in the ubiquitination patterns between subtypes. Polyubiquitination and 
monoubiquitination serve to downregulate proteins in proteasomes and lysosomes, respectively. 
The amino acid sequence of M1, M3 and M5 receptors are similar and have significant variation 
compared to M2 and M4 receptors, which have similar sequence (Hulme et al., 1990). Consistent 
with the sequence homology, M1, M3 and M5 receptor downregulation is inhibited by proteasomal 
inhibitors while M2 and M4 receptor downregulation is inhibited by lysosomal inhibitors. 
4.3 Characterization of the role of the third intracellular loop and C terminal tail of 
M1receptors 
We wanted to determine domains in M1 receptor responsible for agonist-induced 
downregulation. Since internalization is required for downregulation, we wanted to make deletion 
mutations without affecting agonist-induced internalization. Lameh and Philip (1992) made 
several deletion mutants in the third intracellular loop region and C-terminal tail region of M1 
receptors in pursuit for identifying domains responsible for agonist-induced internalization. Out 
of the several mutations made by them, we selected two deletion mutants which internalized and 
signaled to similar extents as wild-type M1 receptors. One of the mutant had a domain in the i3 
loop deleted (M1 del 276-282) while the other mutant had a deletion in the C-terminal tail (M1 del 
447-459). In this investigation, we created the two deletion mutant versions of M1 receptors (M1 
del 276-282 and M1 del 447-459) using site directed mutagenesis and expressed stably in CHO 
cells. The affinities of the mutant M1 receptors for [
3
H]NMS were comparable to that of wild-type 
M1 receptors. However, the potency (EC50) of mutant receptors was at least 3-fold greater than 
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that of wild-type M1 receptors. The maximum response (Emax) of the mutant receptors in response 
to carbachol was considerably different from the wild-type receptor. M1 del 276-282 receptors 
expressed lesser number of receptors (see Table 8) and signaled 1.5 times greater than the wild-
type receptor (see Table 7 and Figure 11). Since agonist-dependent signaling is enhanced in M1 
del 276-282 receptors, desensitization might be affected. This is in agreement with previous 
studies performed by Jewell-Motz and Ligget (1995) in CHO cells expressing α2C2 adrenergic 
receptors. They identified a string of acidic amino acids in the i3 loop of α2C2 adrenergic receptor 
to be involved in desensitization and agonist-induced phosphorylation. Deletion mutants lacking 
this acidic domain internalized to the same extent as wild-type receptors and bound to antagonist 
with a comparable affinity as wild-type receptors. Studies performed using peptide substrates 
have identified that a stretch of acidic amino acids N terminal to the Ser, Thr phosphorylation 
sites serve as the GRK2 binding domains on the receptor (Chen et al. 1993; Onorato et al. 
2002).The consensus sequences of phosphorylation of various second messenger dependent 
kinases such as PKA and PKC have also been identified. None of these consensus sequence 
match the acidic sequence, we deleted (Kennelly and Krebs 1991). The consensus sequence of 
casein kinase 1 binding domain is a stretch of acidic amino acids N terminal to the 
phosphoacceptor serine/threonine (Kennelly and Krebs 1991). M1 receptors have been known to 
be phosphorylated in an agonist-dependent manner by GRK2 and casein kinase 1(Haga et al 
1996; Waugh et al 1999). Hence, the domain deleted by us in the i3 loop might be a binding site 
for GRK or casein kinase 1 involved in agonist-induced phosphorylation of M1 receptors. 
M1 del 447-459 receptors expressed nearly same amount of receptor as the wild-type 
receptor (see Table 8) but signaled only half the amount as wild-type receptor (see Table 7 and 
Figure 11). Deletion of residues in the C-terminal tail region of M1 receptors decreased the 
potency of M1 receptors. The amount of signaling was also reduced. This could have been the 
result of a conformational change introduced by the deletion mutation. The conformational 
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change could have also caused decreased G protein-coupling as it is known that G protein 
coupling requires amino acids in the cytoplasmic regions of GPCRs (Teller et al., 2001).  
In this study, the rate and extent of M1 wild-type, M1 del 276-282 and M1 del 447-459 
receptor internalization, recycling and downregulation in CHO cells were compared. There are no 
significant differences in the rates and plateaus of internalization between the wild type and 
mutant M1 receptors. In conclusion, the deletion mutations introduced in the third intracellular 
loop region and C terminal region of M1 receptor had no effect on either the rate or extent of 
internalization.  
We observed a significant difference in the initial rates and extent of delivery of M1 wild-
type receptors in the cells treated with carbachol and untreated cells indicating that wild-type 
receptors recycled. The initial rate of delivery of M1 wild-type receptors in carbachol treated cells 
was 2.5 fold greater than the rate in untreated cells. The extent of recovery was significantly 
greater in treated cells and was 1.4 fold greater than in untreated cells. 
In cells expressing M1 del 276-282 receptors, there are no differences in the rate of 
recovery in carbachol treated and untreated cells. The extent of recovery of muscarinic M1 del 
276-282 receptors in carbachol treated cells were not significantly different than the extent of 
recovery in untreated cells. In conclusion, deletion of amino acids 276-282 impaired recycling of 
muscarinic M1 receptors.  
In cells expressing M1 del 447-459 receptors, there are no differences in the rate of 
recovery in carbachol treated and untreated cells. The extent of recovery of muscarinic M1 del 
447-459 receptors in carbachol treated cells were not significantly different than the extent of 
recovery in untreated cells. 
The basal plasma membrane delivery of M1 del 447-459 receptors was significantly 
higher than the basal plasma membrane delivery of M1 wild type receptors in both the rate and 
extent of delivery. This suggests that deletion of amino acids 447-459 in M1 receptors accelerates 
their delivery to the plasma membrane. 
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The downregulation of M1 receptors in response to prolonged treatment with carbachol 
was significantly reduced in the cells expressing either of the deletion mutants studied. This 
suggests that the deleted regions play a role in mediating carbachol-induced downregulation. The 
C terminal tail deletion region (K447-Q459) did not downregulate in response to carbachol 
(Figure 14 and Table 10). Even though internalization remains indifferent between the mutants 
and wild-type receptor until 4 h of carbachol treatment, where a plateau is attained, the extent of 
internalization was significantly different between wild-type and mutant receptors at 24 h of 
carbachol treatment. While internalization of wild-type receptors continues after reaching a 
plateau, the internalization of M1 del 276-282 receptors retains the same plateau even after 24 h 
of carbachol treatment. The internalization of M1 del 447-459 receptors reached a plateau at 4 h 
which is similar to the plateau reached by M1 wild-type or M1 del 276-282 receptor at the same 
time period. At 24 h of carbachol treatment, the internalization of M1 del 447-459 receptors 
decreased. This could be due to increased delivery of receptors to the plasma membrane from the 




H]QNB binding in 
unstimulated cells for M1 wild-type and M1 del 276-282 receptors suggesting that most of the 
receptors reside in the plasma membrane (Figure 14 and Table 10). In contrast, a significant 





H]QNB binding in unstimulated cells (Figure 14 and Table 10).  
4.4 Summary and future directions 
This dissertation represents the comparison of internalization, recycling and 
downregulation of muscarinic receptors expressed in CHO cells. For the first time, the 
comparison of effect of proteasomal inhibitors and lysosomal inhibitors on the downregulation of 
muscarinic receptors expressed in CHO cells was studied. Additionally, a domain in the C 
terminal tail of M1 receptors has been identified to be involved in downregulation of M1 receptors.  
Carbachol treatment caused internalization, recycling and downregulation of muscarinic 
receptors in CHO cells. Subtype-specific differences in the rate or extent or both of 
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internalization, downregulation and recycling of muscarinic receptors were identified. Based on 
these findings, it would be interesting to determine whether there are subtype-specific differences 
in the G protein-coupled receptor kinases and arrestins that interact with the receptors during 
agonist treatment. The type of G protein-coupled receptor kinase (e.g., GRK 2, 3, 5 and 6) and 
arrestin (e.g., arrestin 2 and 3) recruited to a particular muscarinic receptor subtype may be 
responsible for the subtype-specific differences observed in this study. 
Proteasomal inhibitors and lysosomal inhibitors differentially inhibited the 
downregulation of muscarinic receptors. While proteasomal inhibitors inhibited the 
downregulation of M1, M3, M4 and M5 receptors, they enhanced the downregulation of M2 
receptors. The lysosomal inhibitors significantly decreased the downregulation of M2 and M4 
receptors. In summary, there are subtype-specific differences in the mechanisms of carbachol-
induced downregulation of muscarinic receptors. Based on the results obtained, it is clear that 
downregulation of M1, M3 and M5 receptors may happen in the proteasomes. Since ubiquitination 
is a prerequisite for downregulation in the proteasomes, it would be interesting to determine 
whether there are subtype-specific differences in the pattern and number of ubiquitination. Mono-
ubiquitination of proteins have been thought to be a targeting signal for proteins destined for 
lysosomes, while poly-ubiquitinated proteins are known to be degraded in the proteasomes. There 
are seven lysine residues within the ubiquitin molecule. The trafficking of polyubiquitinated 
proteins depends on the lysine residue involved in chain formation. The lysine K48 ubiquitination 
has been shown to be involved in proteasomal degradation, while K63 lysine ubiquitination has 
been shown to be involved in endocytosis and DNA repair (Pickart, 2000). It would also be 
interesting to determine the extraction of GPCRs by proteasomal machinery. 
Deletion mutants were created in the i3 loop and C-terminal tail region of M1 receptors. 
Both the mutants created were functional and were able to bind to the muscarinic receptor 
antagonist NMS. The deletion mutants have an internalization profile similar to that of wild-type 
receptor. The downregulation was affected by both deletion mutants. The greatest effect on 
84 
 
downregulation was seen with the deletion of K447-Q459 amino acids in the C terminal tail. 
Analysis of this domain revealed the possession of a class I SH3 domain ligand and three 
hydroxyl amino acids (Li, 2005). Future studies should be directed towards identifying the 
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Scope and Method of Study: Muscarinic receptors mediate the responses elicited to the 
activation of the parasympathetic nervous system. Specifically, muscarinic receptors 
mediate exocrine glandular secretion, smooth muscle contraction and decreased heart rate 
and contractile force. Five subtypes of muscarinic receptors have been cloned and they 
undergo a process of agonist-dependent regulation, which involves desensitization, 
internalization, recycling and downregulation. This study was designed to characterize 
the kinetics and extent of internalization, recycling and downregulation of muscarinic 
receptors expressed individually in CHO cells and to identify subtype-specific differences 
in these processes. The mechanisms of downregulation of muscarinic receptors expressed 
in CHO cells were also investigated by using proteasomal and lysosomal inhibitors. 
Additionally, deletion mutations were made in the third intracellular loop and C-terminal 
tail region of the muscarinic M1 receptor to identify regions responsible for recycling or 
downregulation. 
 
Findings and Conclusions:  There are subtype-specific differences in the internalization, 
recycling and downregulation of muscarinic receptors. The rank order for carbachol-
induced internalization was M2 > M4 = M5 > M3 = M1. Unlike M2 receptors, M1, M3, M4 
and M5 receptors recycled back to the plasma membrane following 1 h carbachol 
treatment. M1 receptor downregulated to a greater extent compared to other subtypes. The 
downregulation of M1, M3, M4 and M5 receptors was affected by proteasomal inhibitors, 
while lysosomal inhibitors affected the downregulation of M2 and M4 receptors. The M1 
deletion mutants (M1 del 276-282 and M1 del 447-459) signaled through activation of 
phospholipase C activation and were able to bind to [
3
H]NMS. Additionally, the 
internalization of M1 deletion mutants was indifferent from those of the wild-type M1 
receptor. However, both deletion mutants had an impaired recycling and downregulation. 
The C-terminal deletion (K447-Q459) significantly affected the downregulation of M1 
receptor, suggesting a role of this domain in mediating M1 receptor downregulation. 
 
 
 
 
